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ABSTRACT
Cisplatin is a chemotherapeutic agent which is thought to exert its cytotoxic 
effects by causing DNA damage in the form of crosslinks. The precise molecular 
mechanisms involved in the transduction of this damage to a cytotoxic outcome 
are as yet not fully characterised. Resistance to cisplatin is a major clinical 
problem making elucidation of its mechanisms of action and mechanisms of 
resistance to it an important area of investigation.
Genetic suppressor elements (GSE's) are small, randomly generated fragments of 
DNA which are isolated by conferring a selectable phenotype when expressed in 
target cells. They are powerful tools in the elucidation of recessive mechanisms 
of resistance to drug treatment. The work presented here describes the 
characterisation of GSE's generated by DNasel digestion of equalised HeLa total 
cDNA library and isolated by Kirschling and Roninson (Chicago, USA) by 
cisplatin selection. Characterisation of GSE's generated from the random 
digestion of a p53 cDNA library are also included.
The GSE's isolated by Kirschling and Roninson have been transfected into the 
human ovarian adenocarcinoma cell line, A2780, and selected using cisplatin. 
Further examination of these cell lines revealed that the line generated by 
transfection of GSE 7.10 showed a high level of resistance to cisplatin (2-3.8 fold) 
and a high level of cross-resistance to an additional DNA damaging agent, 
ionising radiation. I have shown, by PCR amplification, that the GSE 7.10 
construct is present in these transfectants and confirmed by DNA sequencing that 
it is 100% identical to a 188bp fragment of the human phosphoglycerate mutase-B 
gene. Analysis of the cell cycle checkpoints of these transfectants in response to 
DNA damaging agents has revealed that GSE 7.10 abrogates the Gl/S checkpoint 
in response to ionising radiation, and suggests a reduction in the same checkpoint 
arrest in response to cisplatin. I have also purified and sequenced four of the p53 
cisplatin GSE's and confirmed that they are fragments of the p53 gene.
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Chapter 1 Introduction
Chemotherapy has proved to be clinically successful in the treatment of many 
cancers. One of the main obstacles however to the ability to cure cancer is the 
resistance of many tumours to chemotherapeutic drugs and the lack of 
understanding of the mechanisms involved in this resistance. Understanding the 
precise mechanisms of action of chemotherapeutics should facilitate the 
circumvention of resistance and lead to the generation of novel, more selective 
agents.
One of the most successful groups of anti-cancer agents are the platinum co­
ordination complexes, including czs-diamminedichloroplatinum(II) known as 
cisplatin (CDDP). This is an effective treatment for a variety of malignancies 
such as ovarian, testicular, bladder and head and neck tumours (1), and the main 
reason for treatment failure is believed to be the selective outgrowth of a drug 
resistant cell population.
The aim of work presented here was to characterise novel genetic suppressor 
elements which confer resistance, in vitro, to cisplatin in human tumour cell lines. 
In order to understand the approaches I have taken, it is important to understand 
the mechanisms involved in cisplatin toxicity and the cellular responses to 
cisplatin treatment. I have presented a description of what is known about the 
DNA damage which cisplatin induces and the pathway(s) leading from this 
damage to cell cycle arrests and / or apoptosis, processes which ensure that 
damaged DNA is not passed on to subsequent cellular generations. I have also 
described the genetic suppressor element approach in identifying novel recessive 
mechanisms of drug resistance.
2
1.1 Cisplatin Discovery
Cisplatin was discovered in 1965 by Rosenberg (2) as a consequence of 
administering an AC current to E.coli via platinum electrodes. This treatment 
prevented the bacteria from dividing and resulted in filamentous growth which is 
indicative of an SOS response to DNA damage. This was subsequently shown to 
be a result of a compound formed on the electrodes, i.e. cisPt(II) (NH3 )2 Cl2 - 
Investigation in various mammalian tumour cells (3) (including carcinomas, 
sarcomas and leukaemias) revealed that this compound is active as a anti-tumour 
agent in the cis conformation, whereas the trans isomer is inactive. In 1979, 
cisplatin was approved as an anti-tumour drug.
Figure 1.1.1 Chemical Structure of Cisplatin
Cisplatin is a neutral, square, planar co-ordination complex, which, when in the 
low intracellular chloride concentration environment, becomes an active, charged 
electrophile by substitution of the chloride groups by hydroxyls. As an electrophile 
it is capable of reacting with nucleophiles, such as nucleic acids.
3
1.2 Mode of Action of Cisplatin
1.2.1 DNA As The Target Of Cisplatin
The precise molecular mechanism of cisplatin cytotoxicity is uncertain, but there is strong 
evidence to suggest that the primary cytotoxic target of this drug is DNA. 1% of 
cellular cisplatin binds DNA and has been shown to induce various lesions within 
DNA, including monofunctional adducts, inter- and intra- strand crosslinks and 
DNA-protein crosslinks. The most common lesion (65%) is a 1,2 d(GpG) 
intrastrand crosslink, i.e. between two adjacent guanine bases, and studies suggest 
that this is the cytotoxic lesion resulting from cisplatin treatment (4, 5, 6). It has 
been observed that this type of crosslink is poorly repaired (7), possibly due to the 
binding of the HMG1 protein or proteins containing a HMG box (8). The trans 
isomer of the platinum co-ordination complex also induces lesions in DNA, but not 
the 1,2 d(GpG) intrastrand crosslink. The transplatin-induced lesions are more 
rapidly repaired than those caused by cisplatin and it is thought that it is the 
persistence of cisplatin-induced lesions which accounts for its higher cytotoxicity 
(9).
1.2.2 Responses to DNA Damage
Cell cycle arrest and apoptosis appear to be the two most important consequences 
of various types of DNA damage (10). Both of these processes ensure that the 
damage is eliminated from the cellular population, by allowing time for DNA repair 
prior to replication, or by destroying cells containing damaged DNA, respectively. 
Persistence of this damage could potentially lead to the generation of a population 
of cells with a transformed phenotype, so it is vital that the appropriate signal 
transduction pathways, downstream of DNA damage, are functioning correctly. 
One can envisage that interference in these pathways would be a possible 
mechanism of acquiring resistance to DNA damaging agents such as cisplatin.
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1.3 Cell Cycle Control
1.3.1 Early Characterisation
In order to understand the consequences of cisplatin induced DNA damage, a 
description of the basic controls governing eukaryotic cell cycle progression is 
detailed in figure 1.3.1 and below.
The term ‘cell cycle* incorporates all of the events which every cell undergoes from 
its release as one of the progeny of a parental cell, to its own division into two 
daughter cells. The cell cycle is divided into two main compartments, interphase 
and mitosis, both of which can be sub-compartmentalised. Essentially, interphase 
is the period during which the cell undergoes growth and replicates its sub-cellular 
components, including its DNA. Mitosis is the process of DNA segregation into 
two compartments which, as a result of cytokinesis, become two daughter cells.
In the early 1970’s Rao and Johnson (11, 12) attempted to identify controls 
involved in the progression of the cell cycle. They employed cell fusion 
experiments using cells arrested in various phases of the cell cycle i.e. G1 + M, S + 
M and G2 + M. In all three cases, premature chromosome condensation occurred, 
indicating that there is a dominant factor in M-phase cells which drives cells 
towards cell division.
Much of the early investigation into the biochemical regulation of the cell cycle 
was carried out in the 1970’s in the budding yeast S.cerevisiae and the fission yeast 
S.pombe (13, 14). This work yielded a great deal of information on the molecules 
controlling the cell cycle and their interactions. Many of these molecules exhibited 
a large degree of homology between these two yeast, suggesting that the 
mechanisms of control were evolutionarily conserved. This was confirmed by 
investigations in higher organisms including sea urchins, clams and Xenopus and 
also in mammalian systems (15).
5
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cell cycle
The work in yeast revealed the presence of checkpoints in the cell cycle which 
were required to ensure that the cell division process was successful. In 
S.cerevisiae, the major checkpoint has been shown to be at the G1 to S phase 
boundary, the START site where a decision occurs as whether to mate, quiesce, or 
enter S phase and replicate DNA. Commitment to cell division beyond this point is 
irreversible and so facilitated the identification of £ell division £ycle (CDC) 
mutants, including the CDC28 and CLN1, 2, and 3 genes. These were 
subsequently shown to be homologous with the cyclin dependent kinases and 
cyclins, respectively, in mammals. Genes which are important in the S / G2 / M 
transitions were also identified, but S.pombe proved to be the more appropriate 
organism for this work, as its major checkpoint is at G2 / M.
In S.pombe, the G2/M checkpoint appears to be the most highly regulated and its 
transition is dependent upon cell size. Again, cell cycle mutants revealed important 
molecular components of the cell cycle machinery. A protein kinase homologue of 
the S.cerevisiae CDC28 protein was identified and named cdc2, this was found to 
function at both the Gl/S and G2/M checkpoints. Homologues of the cyclins were 
also identified and were, in many cases, shown to substitute for the equivalent 
S.cerevisiae protein.
Work by Masui (16) on Xenopus oocytes, also in the early 1970’s, revealed the 
importance of a maturation promotion factor in the development of the ovum to an 
egg i.e. the progression from G2 of meiosisl to metaphase of meiosisll. This 
progression is similar to the G2/M transition in mitosis. In the 1980’s, MPF was 
purified by Mailer (17) and was identified as a complex of a 34kDa protein and a 
45kDa protein. The 34kDa component was shown to be homologous to the cdc2 
protein of S.pombe and CDC28 of S.cerevisiae and the 45kDa protein to be a 
cyclin homologue.
Studies carried out by Tim Hunt in sea urchin eggs (18) identified 2 proteins with 
distinct patterns of expression during development i.e. reaching a maximum at 
mitosis and decreasing rapidly around metaphase. These have been identified as
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cyclins A and B i.e. G2/M cyclins. The cyclin family has expanded rapidly in 
mammalian systems (A-H to date), all sharing sequence homology and usually a 
pattern of cyclical expression. Cyclins are found in complexes with specific 
partners, the homologues of the CDC28 and cdc2 proteins, termed cyclin- 
dependent kinases (cdk’s) (19).
1.3.2 Cell Cycle Genes : Response To DNA Damage
The genes described above are essentially involved in the control of the normal cell 
cycle, but many genes involved in DNA damage detection and repair have also 
been identified in yeast. The RAD9 gene of S.cerevisiae was identified by Weinert 
and Hartwell (20) as being essential for the arrest of cell division following DNA 
damage. Irradiated rad9 cells do not arrest at the G2 checkpoint as wild-type cells 
do, but continue to divide with damaged DNA and die after several rounds of 
replication. Mammalian cells in culture have been shown to arrest at the G2 
checkpoint in response to cisplatin treatment (21), an arrest which is hypothesised 
to be dependent on the number of cisplatin adducts formed. The p53 tumour 
suppressor protein may play a role in this arrest but a comprehensive genetic 
explanation for this arrest has not as yet been presented. The response to cisplatin 
treatment has also been examined in S.pombe (20). Cells which are mutant for a 
protein kinase, weel, which normally regulates cdc2 activity fail to arrest following 
treatment with cisplatin and those with an abrogated G2 arrest are hypersensitive 
to this drug. It appears therefore that cell cycle arrest is an important determinant 
of cisplatin sensitivity in yeast as well as mammalian cells. A whole family of RAD 
genes have been identified in Sxerevisiae, as well as homologous genes in 
S.pombe, suggesting a high level of evolutionary conservation in the response of 
cells to damaged DNA. Additional genes have been identified which are essential 
for G2 and S phase arrests (22) and whose protein products interact with various 
Cdc proteins, examples include the MEC genes and other RAD genes. It is
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apparent that it is not only the genes involved in the regulation of the normal cell 
cycle which are evolutionarily conserved.
A human genetic disease, ataxia telangiectasia (AT), illustrates the conservation of 
the pathways which ensure the correct response to DNA damage. Individuals with 
AT display several disease-state characteristics, including an increased 
susceptibility to cancers of approximately 100-fold (for a recent review see (23) 
and references therein). This autosomal hereditary disease also correlates with an 
ability of cells to continue DNA replication in the presence of DNA damage, a 
feature indicative of a loss of the Gl/S phase checkpoint arrest. These individuals 
have also been shown to be hypersensitive to X-rays and radio-mimetics known to 
cause DNA double strand breaks. Mutations in the ATM  gene have been shown 
to be responsible for the AT phenotype. The gene has been cloned and sequenced 
and shows homology with the phosphatidylinositol 3-kinases from both mammals 
and yeast, suggesting that the gene may be involved in signal transduction. A 
number of recent papers have shown that there is also a high degree of homology 
with other yeast genes {S.pombe and S.cerevisiae) such as the TOR gene family, 
MEC1, TEL1 and rad3, mutations in which result in cell cycle defects in terms of 
arrest capability, chromosome structure and DNA repair (24, 25, 26, 27).
Studies in yeast have been vital in isolating genes involved in the eukaryotic cell 
cycle, both in the normal situation and in response to DNA damage. The degree of 
evolutionary conservation and number of genes involved in cell cycle controls 
illustrates the importance of this process and its importance in human disease 
states, particularly the development of a transformed phenotype.
1.3.3 Control Of CDK~ Cyclin Activity
From the work in yeast and invertebrates, cdk's were shown to be responsible for 
cell cycle progression in concert with a variety of cyclin partners and control of 
these cdk~cyclin complexes is vital for the correct progression of the cell cycle. 
Cell cycle checkpoints help to ensure that a perfect copy of DNA is passed on to
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daughter cells. The Gl/S checkpoint ensures that DNA is intact and undamaged 
before replication proceeds and the G2/M checkpoint appears to ensure that DNA 
replication has been successfully completed before cell division occurs. It is the 
cdk~cyclin complexes which are the targets of the signal transduction pathway 
from DNA damage to cell cycle arrest (19).
Normal regulation of these complexes is governed by the activation and 
deactivation of the cdk component by dephosphorylation and phosphorylation 
respectively. This is controlled by kinases and phosphatases which also have 
homologues in S.pombe and S.cerevisiae. The mammalian homologue of S.pombe 
weel is responsible for phosphorylating cdc2 (the main G2/M cdk) on a tyrosine 
residue thus rendering it inactive and cdc25 for dephosphorylating the tyrosine 
residue and activating the protein. In turn, various kinases and phosphatases are 
responsible for activating and de-activating weel and cdc25 (28).
Recently, a number of mammalian cdk inhibitors have been identified which are 
induced in response to DNA damage and various growth signals (19). These 
function by directly binding to the cdk’s rather than causing a subtle post- 
translational modification. Waf-1 (Cipl, p21, Sdil), which is a universal cdk 
inhibitor, was identified by several groups as a protein being induced by wild type 
p53 (29, 30), as a protein which interacted with cdk's and a cyclin and as an 
inhibitor of DNA synthesis in senescent cells. Its control is described in more 
detail in section 1.3.4 but it is responsible for arrests at the Gl/S checkpoint in 
response to DNA damage, and can also inhibit DNA synthesis (31).
1.3.4 The Role of p53 In The Signal Transduction Pathway
From DNA Damage To Cell Cycle Arrests
The integrity of the DNA damage response pathway is crucial if DNA damaging 
agents such as cisplatin are to be cytotoxically effective. Modulation of various 
steps in the pathway may allow the sensitivity of cells to these agents to be
10
increased. A summary of the response pathway is shown in figure 1.3.2, 
indicating the points which are as yet uncharacterised.
In response to DNA damage, caused for example by cisplatin, it is hypothesised 
that the damage is detected and a signal transduction pathway is initiated. A DNA 
double strand break is known to induce p5 3-mediated cell cycle arrest (32), 
although the initial molecular DNA damage detector for cisplatin has not been 
identified. Several DNA damage recognition proteins (DRP's) have been 
characterised. Chu and Chang (33) and McLaughlin et al. (34) identified factors 
which recognised cisplatin-induced DNA damage and were elevated in cisplatin 
resistant cells, and Donahue et al. identified an additional factor (35) recognising 
the predominant cisplatin DNA lesion, d(GpG). Hughes et al. used a damaged 
DNA affinity precipitation technique to identify proteins which bound to cisplatin- 
induced DNA lesions, but not to undamaged DNA (36). The two predominant 
proteins were N-terminally sequenced and shown to be identical to the HMG-1 
and HMG-2 proteins.
p53 is a nuclear phosphoprotein of 393 amino acids, the gene for which is mutated 
or lost in more than 50% of human tumours (37, 38). It has an N terminal acidic 
transactivation domain, a central region which contains very highly conserved 
sequences and has a sequence-specific DNA binding activity. The C-terminal 
domain contains the nuclear localisation sequences as well as regulatory 
phosphorylation sites, and is responsible for the oligomerisation of p53 dimers 
and tetramers. A schematic diagram of the functional regions of p53 is shown in 
fig. 1.3.3. The protein is highly regulated, and its main role appears to be that of a 
DNA sequence-specific transactivator.
The p53 tumour suppressor protein has been shown to bind to a certain type of 
damaged DNA in vitro and form stable complexes (39). The damage was not 
however of the type induced by cisplatin but contained insertion deletion 
mismatches. Whether p53 has a direct role, in vivo, in the recognition of DNA 
damage remains unanswered, but evidence for the involvement of p53 in the
11
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pathway leading from DNA damage to cell cycle arrests (and apoptosis) is very 
strong. p53 is involved in cell cycle progression and the normally unstable p53 
protein is stabilised in response to DNA damage. It has been shown in p53 null 
transgenic mice however, that there is not an absolute requirement for p53 in the 
normal cell division cycle as these mice develop fully (40). These mice have a 
higher than normal incidence of tumours, suggesting that p53 plays a role in 
preventing abnormal or deregulated growth. This is supported by the observation 
that transfection of p53 into p5 3-deficient tumour lines restores G1 arrest (41) as 
does a shift to the permissive temperature of a ts' mutant of p53 (42). Conversely 
dominant negative mutants of p53 have been shown to oligomerise with wild-type 
p53 and so abrogate its transactivating function (43), as well as abolishing their 
G1 arrest in response to DNA damage (44).
What involvement does p53 have in the response to DNA damage? The p53 
response of cells following genotoxic insults such as UV, X and y irradiation and 
cisplatin have been investigated. The kinetics of the p53 responses differ and 
appear to be cell type dependent (45, 46). Work on G1 arrest following treatment 
with DNA damaging agents suggests that p53 is involved in the Gl/S checkpoint 
and possibly the G2/M checkpoint (47), but there appear to be alternative or 
additional mechanisms involved. p53-dependent G1 arrest in response to DNA 
damage can be abolished by viral proteins such as HPV E7 and E6 (48). The 
evolutionary function of these proteins is presumably to allow host cell replication 
to continue unhindered and so increase the amount of virus produced. Inhibition 
of the G1 arrest by the E6 protein occurs as it targets p53 for degradation. The E7 
protein acts via an interaction with the retinoblastoma protein. The loss of p53- 
dependent G1 arrest can also be mediated by activated oncogenes e.g. H-ras (49). 
How does p53 induce a Gl/S arrest in response to DNA damage? p53 has a 
positive transcriptional activity and can interact with a number of proteins which 
are thought to be important in the cell cycle, some of which are transcription 
factors. It is thought that interaction with transcription factors reduces the
14
capability of the cell to undergo general transcription, while the transactivating 
activity of p53 results in gene-specific transcription. Several transcriptional 
targets of p53 have been identified, including WAF-1 which is an inhibitor of 
cdk's. Cyclin G was recently identified as being induced by p53 (50), but its role 
in the prevention of tumorigenesis is, as yet, uncharacterised. GADD45 (51), a 
protein involved in growth arrest following DNA damage is also known to be 
transcriptionally activated by the p53 protein. The mdm2 protein is thought to be 
involved in a negative feedback loop to terminate p53 activity (52). After 
induction by p53, mdm2 protein binds p53 near its N-terminal, in the acidic 
transactivation domain, thus blocking the transactivating function of the protein. 
Waf-1 is an inhibitor of cdk's and can block the activity of several cdk~cyclin 
complexes. It functions by forming a quartemary complex with cdk / cyclin / 
PCNA (proliferating cell nuclear antigen) (53). As a result, the kinase activity of 
the cdk is deactivated and downstream targets, such as the retinoblastoma protein, 
whose phosphorylation is required for cell cycle progression, remain 
hypophosphorylated. PCNA is part of the DNA polymerase 8 holoenzyme, which 
is active in DNA replication. This polymerase is primarily thought to be involved 
in DNA elongation, an activity which is curtailed when PCNA is bound in the 
quartemary complex of cdk / cyclin / PCNA / waf-1. This sequestration of PCNA 
does not however prevent DNA repair from occuring (54). This is logical when it 
is considered that the primary fuction of a Gl/S arrest is for DNA repair to occur 
prior to replication. In transformed cells, formation of this quartemary complex 
has not been identified. This observation helps to explain the molecular reasons 
underlying the lack of G1 arrest in many transformed cells in response to DNA 
damaging agents and suggests that the inadequacy is upstream of waf-1 in the 
DNA damage response pathway. As such, waf-1 levels should provide an 
indication of whether it is the upstream p53 response which is being compromised 
in a cell incapable of damage-induced cell cycle arrests.
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1.4 Apoptosis
Apoptosis is an active process of programmed cell death, distinct from necrosis, 
first identified by Kerr et a l (55, 56). It is characterised morphologically by cell 
swelling, nuclear chromatin condensation and changes in the cell surface. This is 
followed by release of apoptotic bodies which are removed by the phagocytic 
action of neighbouring cells. These morphological features are accompanied by 
non-random degradation of DNA into fragments of various defined sizes, those 
associated with chromatin domains i.e. approximately 50kb and intemucleosomal 
fragments of 200bp. Fragments of 30kb have also been identified in response to 
cisplatin treatment (57).
The importance of apoptosis in preventing the development of transformed 
populations of cells is now largely undisputed. Not only are cells exposed to a 
large number of environmental toxins, but they are victim to their own inherent 
DNA replication and repair errors. There is the potential for two transformed cells 
to result from every cell division cycle, and viewed in this light, the rate of tumour 
development in each individual is surprisingly low. Apoptosis results in the 
removal of cells which have the potential to result in an expanded population of 
transformed cells. In this way, the survival of a single cell is forfeited in favour of 
the survival of the individual.
Many groups have helped to characterise the molecular signals which result in 
apoptosis, for example, Evan et a l showed that deregulated c-myc in serum 
starved rat fibroblasts leads to the apoptotic response (58). The p53 tumour 
suppressor protein has also been implicated in the apoptotic response in various 
lines in response to insult with various agents. Lowe et a l have shown distinct 
cases where apoptosis is dependent or independent of p53 function. Using 
thymocytes from transgenic p53 mice, glucocorticoid-induced apoptosis occured in 
p53 null lines, whereas radiation-induced apoptosis required the presence of p53 
(59). Antisense p53 mRNA has been used to suppress growth factor withdrawal-
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induced apoptosis in acute myoblastic leukaemia cells (60), thus emphasising the 
fact that p53 appears to play a pivotal role.
The purpose of chemotherapeutic treatment is to destroy the transformed cell 
population, whilst leaving normal tissue intact. Apoptotic cell death appears to be 
crucial to this process and a review by Dive and Hickman (61) details cellular 
responses to anticancer agents with respect to apoptosis. A linear relationship 
between cytotoxic agent dosage (including cisplatin) and apoptotic response has 
been recorded (62), and a CHO line shown to be deficient in DNA excision repair 
has been shown to be more sensitive to cisplatin treatment than the wild type CHO 
line. Exposure of the BM13674 cell line to cisplatin and other cytotoxic agents is 
known to result in apoptosis, yet it has recently been shown that okadaic acid, a 
tumour promoter and an inhibitor of protein phosphatases, prevents this apoptotic 
response (63). Blocking the apoptotic response of DNA-damaged cells provides a 
logical explanation for the importance of apoptosis in preventing tumour 
development. Cisplatin also induces apoptosis in an ovarian carcinoma cell line, 
CHI (57), and has been shown to kill proliferating rather than quiescent rat 
thymocytes (64). As a common feature of transformed cells is their ability to 
undergo rapid cell division cycles, selective activity of anti-cancer drugs towards 
proliferating cells would prevent the killing of large numbers of normal cells.
The precise mechanisms of apoptotic cell death remain to be defined, but it is clear 
that a large number of factors are important, including extracellular growth signals, 
p53 status, proliferative state and the nature of the cellular insult.
1.5 Resistance To Anticancer Agents
There are many mechanisms which play a part in tumour-drug resistance, those 
which involve problems of delivery and other inherent and acquired mechanisms.
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Delivery of drugs to a tumour site can be problematic as a result of alterations in 
the blood supply as well as other physiological and pharmacological factors. 
Different tumours exhibit different sensitivities to various drugs, for example, cell 
lines derived from bladder tumours are inherently more resistant to cisplatin 
treatment than testicular tumour-derived lines (65). There are a large number of 
possibilities as to why differential sensitivities arise, some of which are described 
in the following section.
1.5.1 Preventing Drug / Target Interactions
Acquired drug resistance results from a phenotypic change in the tumour in 
response to treatment, and can be imitated by selection of cells with drug in vitro 
(66, 67). A schematic diagram of various methods of acquired drug resistance are 
shown in Figure 1.5.1.
Changes in the accumulation of cytotoxic drugs can occur as a result of an 
increase in drug efflux and / or a decrease in drug influx. This has been 
characterised in the MDR (multi-drug resistant) phenotype, initially identified in 
the late 1960's (68, 69). Drug-selected cells were shown to have a lower level of 
drug accumulation than the parental cell line, a feature which was later identified 
as a result of overexpression of the MDR1 gene product (70, 71) due to 
amplification of the MDR1 gene (72). Increased expression of the MDR1 gene 
product, p-glycoprotein, has been identified in inherently resistant tumours and 
several relapsed tumours. P-glycoprotein is a integral membrane protein with an 
ATP binding domain and shows homology with transport proteins (73). It is 
therefore hypothesised that it acts as an energy-dependent efflux pump which can 
bind to various drugs and pump them out of the cell. This phenomenon however 
does not play a role in the clinic and in relapsed tumours in terms of cisplatin 
resistance (74, 75). An additional method of reduced drug accumulation is 
binding to extracellular proteins, such as serum proteins (76). Reduced 
accumulation of drug does not appear to be a physiologically relevant explanation
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Figure 1.5.1 Schematic diagram of the mechanisms of drug 
resistance.
for cisplatin resistance although examples of cisplatin resistant lines with 
differential uptake levels have been observed (77, 78).
Intracellular molecules may also be responsible for 'sequestration' of cisplatin by 
reacting with it and so abolishing its reactivity. For example, nucleophiles such as 
the tripeptide glutathione (GSH) and the metallothionein (MT) proteins can react 
with cisplatin, so reducing its effective concentration and cytotoxicity. Although 
increases in GSH and MT intracellularly have been shown to correlate with 
increased resistance to cisplatin, this does not appear to be clinically important in 
the case of GSH and not a direct result of MT concentration (79).
1.5.2 DNA Repair and Adduct Tolerance
It can be envisaged that if a cell can rapidly repair DNA damage or tolerate greater 
levels of damage then it may display increased viability. It has been shown that 
cisplatin-DNA adducts can be repaired by nucleotide excision repair (80) although 
this may not be the only mechanism of repair of cisplatin-induced DNA damage. 
Several cisplatin-resistant cell lines have been shown to have increased DNA 
repair by ^H-thymidine incorporation and loss of adducts (81, 82). This supports 
the hypothesis that it is the amount of damage which is the pertinent factor in the 
sensitivity of cells to cisplatinJ In addition, a cisplatin-sensitive testicular line has 
reduced removal of intrastrand crosslinks as a result of cisplatin treatment 
compared with a cisplatin-resistant bladder line (83), strongly suggesting a role for 
DNA repair in determining the level of cisplatin resistance. In turn, this 
substantiates the evidence that the primary cytotoxic target of cisplatin is DNA.
1.5.3 Identification of Novel Resistance Mechanisms
As resistance to cisplatin has been shown to be clinically relevant, circumvention 
of this resistance should allow cisplatin treatment to be used to its most effective 
chemotherapeutic potential. As many tumours and cell lines exhibit a multi-drug 
resistance phenotype, independent of p-glycoprotein expression, identifying genes
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involved in the resistance to cisplatin may elucidate general mechanisms of 
resistance for a large number of DNA-damaging agents. Identification of the most 
sensitive components of the DNA damage-induced cytotoxic pathway(s) should 
also aid the design of novel drugs and treatments.
Many of the genes which have been linked to drug resistance to date, have been 
identified as being elevated in the resistant phenotype. The relevance of the 
elevation of the MDR-1 gene product, p-glycoprotein, has been described 
previously (84) but appears to have little relevance in resistance to cisplatin. 
Other gene products which have been identified as elevated in resistant cell lines 
include the bcl-2 protein. Bcl-2 is a negative mediator of the apoptotic response 
(85), but there is a large amount of data detailing the importance of a family of 
bcl-2-related proteins which act in concert to control its activity (86). MDM2 is 
an oncogene and the protein has recently been shown to confer resistance to 
cisplatin-induced apoptosis in a human glioblastoma cell line when overexpressed 
(87). As mdm2 is thought to act as a negative regulator of p53 function, it can be 
hypothesised that overexpression blocks the apoptotic function of p53 and so 
DNA-damaged cells survive. As mentioned in sections 1.3.4 and 1.5.2 
respectively, damage recognition proteins and proteins involved in DNA repair 
have also been shown to be elevated in particular resistant tumours and cell lines 
(88, 67). Lu et al. (89) have recently identified a cisplatin-resistance locus (crll), 
which, when overexpressed, confers cisplatin resistance. They employed a 
retroviral insertional mutagenesis strategy to identify this sequence i.e. pro viral 
insertion resulted in an increase in expression from the retroviral promoter, and 
cells were selected for resistance to cisplatin treatment. The insertion site was 
then mapped. This system could of course have identified a locus, down- 
regulation of which resulted in resistance.
Recessively acting genes i.e. those genes in which a decrease in activity of gene 
product causes drug resistance, have been investigated less extensively. Loss of
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heterozygosity and dominant negative mutations are often the causes of reductions 
in protein activity in vivo and may result in a resistant phenotype. Experimentally, 
dominant negative mutants of particular genes have been transfected into cells in 
culture to examine the role of reduction in protein activity. For example, 
transfection of the dominant negative mutant of the p53 gene, Valj4 3  > Ala, into 
the A2780 cell line has been shown to correlate with a loss of the phenotypic 
characteristics associated with wild-type p53 function, such as cell cycle arrests 
(44). This line is also more resistant to cisplatin treatment than the parental cell 
line. Shaulian et al. (43) used a similar approach to examine the functional 
domains of the p53 protein. They generated C-terminal miniproteins of the p53 
tumour suppressor protein and demonstrated that these fragments reduced p53 
activity as determined by DNA binding and transformation assays i.e. these 
protein fragments or ‘ miniproteins ’ abrogated the activity of the endogenous, 
wild-type protein. An additional experimental method which has been extensively 
used to examine the effect of a reduction in the activity of an endogenous gene 
product is the introduction of antisense mRNA which can hybridise to the mRNA 
transcribed from the wild-type gene thus preventing its translation into protein. 
Antisense mRNA targetted at MDM2 was used to examine the result of a 
reduction in mdm2 protein in a human glioblastoma cell line (87). The result was 
an increase in the sensitivity of this cell line to treatment with cisplatin, 
presumably because p53 activity was not downregulated by mdm2 binding.
In an attempt to identify mechanisms of resistance resulting from a decrease in the 
activity of a gene product Gudkov et al. have taken an alternative approach. They 
have developed a technique using genetic suppresser elements (GSE's) in an 
attempt to identify recessive mechanisms of drug resistance (90).
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1.6 Genetic Suppressor Elements
Genetic suppressor elements or GSE's are small gene fragments which, when 
transfected into a cell line, can act to suppress the level or activity of the protein 
synthesised from the full length wild-type gene. This gene fragment can act in 
antisense to decrease the amount of translated protein or in a sense orientation to 
decrease protein activity by a dominant negative mechanism. It is also possible 
that a GSE, which has sequence or conformational homology with the mRNA or 
protein encoded by a different gene, may reduce the level or activity of that 
protein. It can therefore be envisaged that this GSE approach has many potential 
applications, and could, theoretically, be used to identify genes involved in any 
biochemical pathway of interest. In the context of the work presented here, I have 
used GSE’s to investigate genes involved in cisplatin resistance.
1.6.1 Generating Genetic Suppressor Elements
Figure 1.6.1 outlines the steps involved in the generation and isolation of genetic 
suppressor elements. The library is generated by random digestion of the cDNA 
of interest using, for example, DNasel. The library is normalised to ensure that 
each digested fragment is equally represented. The fragments are ligated into a 
vector with the appropriate restriction sites and resistance markers for selection in 
bacteria and mammalian cell lines, and used to transform bacterial cells. The 
DNA is then isolated and used to transfect a packaging cell line. Packaging cell 
lines are capable of supporting the generation of infectious viral particles, and the 
supernatant from these cells can therefore be used to infect the cell line of interest. 
Infectants are selected using a dominant marker present in the vector and selected 
further for the phenotype of interest e.g. resistance to topo Hoc inhibitors, cisplatin 
etc. Selected lines are therefore generated and the GSE insert can be isolated by 
PCR amplification (the nature of viral infection ensures that, in most cases, each 
cell will be expressing a single GSE). To confirm that the GSE which has been
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Figure 1.6.1 Generation and isolation of gene suppressor elements
isolated is responsible for the selected phenotype, it is then used to re-transfect the 
line of interest, and the selection procedure is repeated.
1.6.2 The Use of Genetic Suppressor Elements To Identify
Recessive Mechanisms Of Resistance To 
Topoisomerase Ila Inhibitors
Gudkov et al. (91) identified GSE's which abrogate the resistance of cells to 
topoisomerase Ila inhibitors such as etoposide. Many inhibitors of topo Ila are 
used in cancer chemotherapy e.g. epipodophyllotoxins and anthracyclines, so 
understanding the reasons for resistance to these drugs is of clinical interest. 
Topoisomerase Ila is an enzyme involved in the negative and positive 
supercoiling of DNA and is therefore important in DNA replication and 
transcription. Topo Ila nicks and rejoins both strands of DNA, to achieve a two­
fold change in DNA linkage number, by the formation of a cleavable complex 
with DNA. Topo Ila inhibitors act to stabilise this cleavable complex which 
contains the topo Ila protein bound to the cut ends of DNA. Prior to Gudkov’s 
work it had been observed that cells which showed resistance to topo Ila 
| inhibitors had decreased levels (or levels of activity) of topo Ila (105) suggesting 
that resistance was in some way due to a reduction in the number of cleavable 
complexes available for stabilisation.
Gudkov et al. attempted to 'artificially' reduce the level of topo Ila activity in 
HeLa cells by introducing DNA fragments derived by the random digestion of full 
length topo Ila cDNA, and examining their activity as topo Ila GSE's (91). This 
GSE approach has proved to be very successful and a number of topo Ila GSE's 
have been identified, including both sense and antisense gene fragments, which 
confer resistance to topo Ila inhibitors. The data also provides evidence for the 
functional importance of protein domains i.e. several of the sense GSE’s derived 
from the topo Ila gene are fragments from the active site of the enzyme. The
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fragments which are not derived from this region of the protein indicate the 
importance of regions with as yet unknown functions.
The same group have also randomly digested total poly(A)+ RNA-generated 
cDNA from NIH3T3 cells and used these fragments to look for resistance to topo 
Ila inhibitors (93). They isolated three GSE's, two from unknown genes and one 
which was derived from the kinesin gene, whose protein product is a microtubule- 
associated motor protein. Although kinesin has not previously been linked with 
responses to drug administration, the GSE was found to confer resistance to a 
number of drugs including etoposide and to a lesser extent cisplatin and increase 
sensitivity to microtubule poisons such as colchicine.
1.6.3 The Use of Genetic Suppressor Elements To Identify
Recessive Mechanisms Of Resistance To Cisplatin
Within Roninson’s group, Deborah Kirschling has generated GSE’s which confer 
cisplatin resistance to human cells (94). These GSE’s were derived by random 
digestion of normalised HeLa carcinoma cell cDNA. A retroviral library was 
generated from these fragments and infectious virus was generated in a packaging 
cell line. The viral supernatant was used to infect HeLa cells and HT1080 
fibrosarcoma cells. Two rounds of selection for infectants with increased 
resistance to cisplatin were performed and the resulting fragments were tested for 
biological activity. To date, 15 cisplatin GSE’s have been identified including 
both sense and antisense fragments from known and novel genes. None of these 
known genes has previously been specifically connected with drug resistance. 
The identity of the GSE's are shown in table 1.6.1. One can envisage however 
that reduction in the activity of a protein involved in DNA repair, apoptosis, 
pyrimidine biosynthesis or signal transduction may play a role in drug resistance. 
It is more difficult to generate a hypothesis for the involvement of a reduction in 
the activity or amount of an extracellular matrix protein or a glycolytic enzyme in 
this phenotype. As mentioned in section 1.6 however, it could be that the GSE's
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are causing a reduction in the activity of a gene product other that from which they 
have been derived.
No. Corresponding Gene Orientation Associated Function
Vector
alone
- - -
1 XRCC1 sense DNA repair
2 TRPM-2 sense Apoptosis
3 Phosphoglycerate mutase B sense Glycolysis
4 CaM Kinase B antisense Signal transduction
5 Dihydrooratate
dehydrogenase
antisense Pyrimidine synthesis
6 Decorin antisense Extracellular matrix
7-15 Unknown - -
Table 1.6.1 Identity and function of the genes from which the 15 cisplatin
GSE's were derived, and orientation of the GSE's.
1.6.4 p53 Genetic Suppressor Elements
The cisplatin GSE's which I have described were isolated from a cDNA library 
generated by digestion of total HeLa cell cDNA. An alternative approach, and 
one that Gudkov has previously employed in the case of topoisomerse Ila, is the 
generation of a gene cDNA library. Liam Gallagher (Dept. Medical Oncology, 
Glasgow University) has generated both human and murine p53 cDNA libraries, 
and using the methods previously described has isolated a number of p5 3-derived 
GSE's which confer resistance to cisplatin. Several of these GSE's have been 
isolated by PCR and DNA sequencing has revealed that they contain sequences of 
the p53 gene in preference over fragments from the vector in which the library 
was generated. This suggests that the GSE approach is a selective one which 
should be capable of identifying novel recessive mechanisms of drug resistance.
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1.7 Tetracycline Inducible Expression System
To confirm any phenotype which correlates with tranfection of a GSE, it would be 
interesting to controllably induce expression of that GSE. Myself and Margaret 
Caimey (Dept, of Medical Oncology, University of Glasgow) are attempting to 
generate an inducible gene expression system based on tetracycline responsive 
elements, as described by Bujard et al. (95), in various cell lines of interest. This 
system is being used in preference to other inducible systems due to its efficiency 
as a very clean on/off switch. Many other inducible systems can 'leak' as the 
element or molecule which is used as the switch is endogenous to the cell line in 
use. For example, the metallothionein and dexamethasone systems both use 
inducer molecules which are often present in cells at a low concentration.
The tetracycline system requires the use of two plasmids, one incorporating the 
transactivator construct, the other carries the tetracycline operator sequence. The 
transactivator consists of the tet repressor sequence from E.coli fused to VP 16 the 
herpes virus transactivator. This construct acts as a transcription factor, the target 
of which is a minimal eukaryotic promotor with a series of tet operator sequences 
and the gene of interest. In the presence of tetracycline, the transactivator binds to 
tetracycline and so is prevented from binding to the operator sequences. As a 
result, the gene of interest is not transcribed. When tetracycline is removed, the 
transactivator is free to bind the operator sequence and transcribe the gene (or 
GSE) of interest. As tetracycline is not an endogenous molecule of mammalian 
cells, expression of the GSE should be high when tetracycline is absent, and the 
concentration of tetracycline required to block expression can be determined using 
a cell line containing a luciferase reporter system, that is, SMI61.
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1.8 AIMS
The aim of the work presented here has been the further characterisation of the 
cisplatin GSE's isolated by Kirschling et al (94). I have specifically concentrated 
on GSE 7.10, that derived from the human phosphoglycerate mutase-B gene for 
reasons which will be described later. I have been able to confirm that this GSE 
does confer resistance to cisplatin in an additional cell line to those described by 
Kirschling et a l , that is the human ovarian adenocarcinoma cell line, A2780. I 
have further investigated their cross-resistance to another DNA-damaging agent, 
ionising radiation and examined their ability to initiate cell cycle arrests after 
exposure to both cisplatin and ionising radiation. I have also carried out some 
initial preparations for developing the tetracycline-dependent inducible expression 
system and examined some of the p53 cisplatin GSE's isolated by Liam Gallagher.
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Chapter 2 Materials and Methods
2.1 Materials
2.1.1 Manufacturers
Chemicals
Restriction Enzymes
Cisplatin
Radiochemicals
Oligonucleotide Primers
Molecular Weight Markers
Antibodies
PCR Reagents
Wizard PCR Clean-Up Kit
Wizard DNA Clean-Up Kit
Prime-It II Kit
Nucleon 1 DNA Extraction Kit 
TRIzol™ RNA Extraction Reagent 
Competent Cells
Plasmid Purification Kits 
Nick Columns 
Transfer Membrane 
Autoradiography Film 
Plastics
Aerosol Resistant Tips 
Tissue Culture Media 
Supplements for Media 
Calcium Phosphate Transfection Kit
Sigma, BDH, Pharmacia, Fluka, Fisons
Gibco BRL, Pharmacia
Sigma
Amersham International
Oswell DNA Service
Gibco BRL
Dakopatts, Sigma
Boehringer Mannheim
Promega
Promega
Stratagene
Scotlab
Gibco BRL
Stratagene (Epicurian Coli SURE)
Gibco BRL (DH5-a Sub-cloning Efficiency)
Qiagen, Flowgen
Pharmacia
Amersham International 
Kodak
Sterilin, Falcon 
Molecular Bioproducts 
Gibco BRL, Globepharm 
Gibco BRL 
Gibco BRL
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Tissue culture plastics 
24 Microwell Plates 
Centrifuges 
FACS Machine 
PCR Machines 
Sequencing 
Sequence Analysis 
Gel Tanks 
X-Ray Developer 
UV Crosslinker
Nunclon, Falcon 
Nunclon, Coming 
Sorvall
Beckton Dickinson
Hybaid, Perkin Elmer
Applied Biosystems Inc. using Dye Deoxy
GCG Package
Pharmacia
Kodak
Stratagene
Laser densitometer: autoradiographs were analysed at a SUN workstation using a 
Molecular Dynamic Densitometer and PDI Quantitation 1 software.
2.1.2 Radiation
All performed using y rays from a 60Co source.
2.1.3 Oligonucleotide Primers
H2693 / N0853 / P1785 (Reverse) AGCTACGTTGCCAAACCTA
H2694 / N0854 / P1786 (Forward) CCTGGAGACGCCATCCAC
2.1.4 Plasmids
Common Features of pUH Tetracycline Plasmids 
From H.Bujard (95).
pBR322 derived plasmid, with a hCMV promoter/enhancer, 
p-lactamase resistance gene.
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Specific Features of pUH Tetracycline Plasmids
pUHD 15-1 
pUHD 151-1 
pUHD 10-3
pUHC 13-3
pUHC 13-4
Contains the tTA gene as a VP16 fusion.
Contains the tTAs gene.
Contains heptamerised upstream tet-operators. 
Multiple cloning site (MCS).
Contains heptamerised upstream tet-operators in two 
different orientations.
Luciferase gene.
Contains heptamerised upstream tet-operators in two 
different orientations.
Luciferase gene.
Other Plasmids 
pLNCX710 pLNCX Accession no. M28247 (96)
Generated by Hindlll / Clal digestion of both pLNCX and 
GSE 7.10, followed by ligation of the plasmid backbone 
with the GSE fragment 
Ampicillin resistance gene.
pIC19R Accession no. VB0092 (97) 
Ampicillin resistance gene. 
MCS.
Lac Z selection
pSVneo (98)
Ampicillin resistance gene. 
Neomycin resistance gene.
pCEP-WAF-l-S (30)
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2.1.5 Solutions
Phosphate Buffered Saline (PBS) 
0.8% NaCl 
0.115% Na2 HP0 4  
0.02% KC1 
0.02% KH2PO4
PBT
PBS
0.1% Tween-20
0.5% BSA fraction V (w/v)
TBE(lx) PH8 
89mM Tris borate 
89mM Boric acid 
2.5mM EDTA
TEpH8
lOmMTris
ImMEDTA
20x SSPE
3.6M NaCl
0.2M NaH2 P0 4
0.02M EDTA pH7.7
made up with DEPC treated water
0.1% DEPC Treated Water 
999ml double distilled H20  
lml DEPC 
Autoclave solution
lOx MOPS RNA Running Buffer
0.2M 4-(N-Morpholino)propane-sulphonic acid
0.05M Na acetate pH7.0
0.01M Na2EDTA
made up with DEPC treated water
lOOx Denhardt's Solution 
2% (w/v) BSA fraction V 
2% (w/v) Ficoll™
2% (w/v) PVP
made up with DEPC treated water
Prehybridisation Buffer 
5x SSPE
5x Denhardt's solution 
0.5% SDS (w/v)
50% formamide (v/v)
made up with DEPC treated water
Formaldehyde Gel Loading Buffer (for Northern blotting! 
50% glycerol 
ImMEDTA (pH8)
0.25% bromophenol blue 
0.25% xylene cyanol FF
DNA Dye Mixture 
30% v/v Glycerol 
0.25% w/v Bromophenol blue 
0.25% w/v Xylene cyanol
X-gal (5-bromo-4-chloro-3-indolyl-p-D-galactosidase)
Prepared in dimethyl formamide.
CIP Buffer 
lOmM ZnCl2 
lOmM MgCl2 
0.1 M Tris*HCl (pH8.3)
Equilibrated Phenol
To phenol (Rathbum) 0.1% (w/v) 8-hydroxyquinoline was added. An equal 
volume of 1M Tris base pH8 was added and, after settling, the upper phase 
discarded. This was repeated. An equal volume of 0.1 M Tris base pH8 and 0.2% 
(v/v) p-mercaptoethanol was added and mixed well. This was left to settle and the 
upper phase discarded. Repeat this step. This was stored at 4°C away from light 
with a small volume of Tris covering the surface.
2.2 Tissue Culture Techniques
2.2.1 General Techniques
Aseptic manipulations were performed using sterilised glassware in a class II 
microbiological safety cabinet with vertical airflow. Cells were grown at 37°C as 
monolayers in supplemented RPMI (Rosswell Park Memorial Institute; see below 
for supplements) medium in the presence of 5% C02. They were stored by
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freezing in RPMI with 10% di-methyl sulphoxide (DMSO) in 1ml cryotubes at 
-70°C and were then maintained in liquid nitrogen. GSE transfected cells were 
regularly exposed to 600pgml'l G418 to confirm the presence of the co­
transfected G418 resistance plasmid.
2.2.2 Tissue Culture Media 
RPMI
88 ml RPMI 1640 (lOx)
800ml sterile distilled water
26.6ml 7.5% Na(C03)2
10ml lOOmM Na pyruvate
10ml 200mM L-glutamine
lml 1M NaOH
100ml foetal calf serum
5ml penicillin / streptomycin (50mg)
Special Liquid Medium
500ml Special Liquid Medium
50ml 200mM L-glutamine
50ml foetal calf serum
2.5ml penicillin/streptomycin (25mg)
liypsin  
20ml lOx PE
25ml trypsin (2.5% stock)
205ml sterile distilled water
2.2.3 Cell Lines
A2780 A human, ovarian adenocarcinoma cell line obtained from
R.F. Ozols and T.C. Hamilton, Fox Chase Cancer Center, 
Philadelphia.
A2780cp70 A cisplatin resistant derivative of A2780. (For a more
complete description of A2780 and A2780cp70 see Behrens 
etal., 1987 (66).)
MCF-7 A human, breast adenocarcinoma cell line (92).
SMI 61 An established murine epithelial cell line transfected with a
luciferase construct driven by the 6kB promoter of the e- 
cadherin receptor.
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2.2.4 Subcloning of A2.14
Cells were seeded at lx l0^ per 90mm diameter dish and incubated for 8 - 12 days. 
Colonies were picked into 25cm flasks using sterile pipette tips.
2.2.5 Clonogenic Assay
Cells were seeded at lx l 0^ per 90mm diameter dish on day 1. Cells were treated 
with either radiation or cisplatin on day 2 after medium replenishment. Colonies 
were grown for 10-14 days then stained with lx Giemsa stain for 10 minutes and 
rinsed.
2.2.6 Cell Cycle Assay
Tissue Culture
Cells were seeded at 2x10^ cells per 90mm tissue dish in supplemented RPMI on 
day 1. On day 4, the medium was replenished prior to treatment with radiation or 
cisplatin. 6, 24 and 48 hours after treatment the medium was replenished with 
supplemented RPMI containing bromo-deoxyuridine (BrdU) at a final 
concentration of lO i^M. After a 4 hour incubation in BrdU, the medium was 
removed and retained, and the cells were lifted by trypsinisation. The combined 
medium and cells were centrifuged at 500xg for 5 minutes and the supernatant was 
discarded. The pellets were resuspended in 5ml of cold 70% ethanol and stored at 
4°C for up to two weeks.
Cell Staining
Cells were pelleted by centrifugation at 500xg for 5 minutes and the supernatant 
was discarded. The pellets were resuspended in 1ml cold PBS and transferred to 
1.5ml microcentrifuge tubes prior to centrifugation at 300xg for 5 minutes at 4°C. 
The cells were again washed in 1ml cold PBS, pelleted as previously and 
permeabilised with 1ml 2M HC1 for approximately 30 minutes. Cells were pelleted 
by centrifugation at 2000xg for 5 minutes at 4°C (these conditions used for all 
subsequent centrifugations unless indicated) and washed twice in 1ml PBS. The
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cells were then resuspended in 1ml PBT as a blocking agent, pelleted and 
incubated with lOOpl of a 1:40 dilution of mouse a-BrdU MAb in PBT for at least 
1 hour at room temperature. Pelleting was followed by two washes in PBT and 
then incubation with secondary antibody, 1:40 dilution in PBT of FITC-conjugated 
a-mouse MAb for at least 30 minutes. The cells were washed once in PBT and 
once in PBS prior to incubation with lmgml'l propidium iodide for at least 20 
minutes at room temperature or overnight at 4°C. The cells were pelleted and 
resuspended in an appropriate volume of PBS in preparation for FACS analysis.
Cell cycle distribution was determined by FACS analysis counting in excess of 
2x10^ events unless otherwise stated.
2.2.7 Transfection Of Plasmid DNA Into Cell Lines
lx l06 cells were seeded in 15ml supplemented Special Liquid Medium per 90mm 
dish on day 1. Medium was replenished on day 2, approximately 3 hours prior to 
transfection. A calcium phosphate transfection protocol was followed to co­
transfect the tetracycline operator plasmid DNA and neomycin resistance marker 
plasmid DNA.
Control transfections were performed using supplied salmon sperm DNA in 
combination with the resistance marker plasmid, a transfection procedure in the 
absence of DNA and also untreated cells. The cells were incubated in the 
transfection mixture for 12 - 16 hours before medium was replenished on day 3. 
On day 4, G418 (geneticin) was added to the cells in fresh supplemented SLM as 
selection. After 8 - 1 4  days incubation, colonies were picked with sterile Gilson 
pipette tips into individual wells of 24 microwell plates containing approximately 
2.5ml supplemented RPMI. Tetracycline was added where required.
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2.3 Nucleic Acid Extractions
All work with RNA & DNA was carried out using autoclaved solutions, where 
appropriate. Disposable gloves and plasticware, autoclaved glass pipettes and 
aerosol resistant tips were used throughout. DNA & RNA quantitation was 
performed using a combination of visual assessment on agarose gels in 0.5x TBE, 
0.5pgml"l ethidium bromide when run against known standards, and 
spectrophotometrically using O.D.260.
Gel apparatus to be used in RNA analysis was washed (99) to destroy 
contaminating RNases : apparatus was washed thoroughly in diluted Decon and 
rinsed. This was followed by a rinse in ethanol, and a 15 minute soak in 3% 
H2 O2 . The apparatus was rinsed in DEPC treated water prior to use. DEPC 
treated solutions were also used where appropriate (see text for details).
2.3.1 DNA Extraction
DNA was extracted from cell lines using the Nucleon 1 kit, following the supplied 
protocol.
2.3.2 Routine Extraction Of DNA
Routine concentration of DNA samples was carried out as detailed. To the DNA 
sample, 0.1 volumes 3M sodium acetate pH8, 2.5 volumes 100% ethanol and 1% 
glycogen was added. The DNA was left on dry ice for approximately 15 minutes 
and then centrifuged at 12000xg at 4°C for 15 minutes. The pellet was washed in 
70% ethanol and DNA was re-pelleted at 12000xg for 10 minutes at 4°C. The 
pellet was air-dried and resuspended in TE pH8.
2.3.3 RNA Extraction
Medium was poured off monolayer cultures of near-confluent cells grown in 
125cm^ flasks. 10ml of TRIzol reagent was added to lyse the cells which were
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then transferee! into sterile 15ml tubes and left at room temperature for 
approximately 5 minutes. 2ml of chloroform:amyl alcohol (24:1) was added to 
each tube. After shaking the tubes for approximately 15 seconds and a 2-3 minute 
incubation at room temperature, the contents were centrifuged at 1600xg at 4°C 
for 20 minutes. The upper aqueous phase was removed to a fresh 15ml tube to 
which 5ml isopropanol was added and left to incubate at room temperature for 10 
minutes. After centrifugation at 1600xg at 4°C for 20 minutes, the supernatant 
was discarded and 10ml 75% ethanol (DEPC treated) was added and the pellet 
was partially resuspended by vigorous vortexing. The pellets were air dried at 
room temperature after a 15 minute centrifugation at 4°C at 1600xg. The pellets 
were resuspended in 50-200pl DEPC treated water in autoclaved 0.5ml eppendorf 
tubes and warmed to 55°C for 5 minutes to aid dissolution. Samples were stored 
at -70°C.
2.4 Polymerase Chain Reaction
Pre and post PCR reagents, reactions and equipment were kept separate in order to 
prevent cross contamination. In addition, aerosol resistant tips were used 
throughout.
2.4.1 PCR Amplification of DNA
To lOpil of DNA, 90pl of 'master mix' was added. Master mix was prepared as 
follows (per sample)_________________________________________________
Taq buffer lOpl
dNTP mix 2pl (from 40mM total concentration stock, each dNTP = lOmM)
primers lpg of each
Taq enzyme 0.4pl
sterile water to total volume of 90pl
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75|il of paraffin oil was added to each sample to prevent evaporation.
The GATC base content of each primer was used to estimate the optimum 
annealing temperature, and the average of the two values was used in the reaction.
2(A+T) + 4(G+C) = annealing temperature 
The reaction was carried out in a Omnigene thermal cycler under the following 
conditions __________________________________
94°C 3 minutes
94°C 1 minute
56°C 1 minute 30 CYCLES
72°C 1 minute
72°C 7 minutes
The PCR products were purified using a Wizard DNA Clean-Up kit and protocol, 
and the products analysed by gel electrophoresis.
2.5 DNA Sequencing
Purified PCR products were amplified prior to sequencing as follows :
PCR product 5pl
primers 3.2pmoles of each
sterile water to final volume of 10.5pl
DyeDeoxy Termination mix 9.5pl
PCR was performed using the following protocol
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Preheat to 96°C
96°C for 15 secs
50°C for 1 sec 25 CYCLES
60°C for 4 mins
Soak 4°C
80pl of sterile water was then added to the reactions and DNA was extracted with 
IOOjj.1 of phenol / chloroform / water at a ratio of 68:18:14 by centrifugation at 
5000xg for 5 minutes. DNA was extracted as detailed (section 2.3.2) The DNA 
was left to air-dry, then sequenced and analysed. Sequencing was performed using 
the dideoxy chain termination technique of Sanger et al. (100) as detailed in the 
protocol which accompanies the DyeDeoxy kit (ABI).
2.6 RNA Analysis
2.6.1 RNA Integrity
To verify the integrity of the extracted RNA, it was separated electrophoretically. 
RNA samples were prepared as follows : to approximately lOpg of RNA, TE pH8 
was added to a total volume of 4pl. The RNA was incubated at 65°C for 10 
minutes then chilled on ice prior to the addition of lp l of DNA running dye. The 
samples were loaded onto a 1.5% agarose gel containing 0.5pgml"l ethidium 
bromide, and run in 300ml 0.5x TBE containing the same concentration of 
ethidium bromide. The gel was run at 7.5Vcm"l for approximately 1 hour. RNA 
was visualised on a UV transilluminator.
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2.6.2 Denaturing Formaldehyde Gel For Northern Analysis
RNA samples were prepared according to the protocol detailed in the Amersham 
Hybond N booklet. To approximately 20pg RNA (final volume made up to 6 pi 
with DEPC treated water) 12.5pl formamide, 4pl formaldehyde and 2.5pl lOx 
MOPS were added. These samples were then incubated at 65°C for approximately 
10 minutes and chilled on ice prior to the addition of 2.5pl of RNA running dye. 6 
pg of 0.24 - 9.6kb RNA ladder was prepared in the same way.
The samples were loaded onto a pre-run (5 minutes at 5Vcm"l) Wo agarose 
denaturing gel prepared as follows : 4g agarose was added to 292ml DEPC treated 
water and 40ml lOxMOPS. The agarose was melted and left to cool to 
approximately 50°C prior to the addition of 68ml formaldehyde and 0.5pgml"l 
ethidium bromide. The gel was cast and left to set in a fume hood. The gel was 
run at 3.5Vcm"l for approximately 5 hours and at lVcm'l overnight. The gel was 
then photographed under UV before transfer.
2.6.3 Northern Transfer of RNA
The denaturing gel was cut to size and the RNA transfered, over approximately 20 
hours, onto Hybond-N membrane using 20x SSC as the transfer buffer. The 
membranes were left to air dry for approximately 10 minutes prior to UV 
crosslinking in a Stratalinker oven.
2.6.4 Hybridisation Of Northern Blots
Blots were pre-hybridised overnight in 25ml of pre-hybridisation buffer at 42°C 
using a Hybaid oven and Hybaid roller bottle system (bottles were rinsed in DEPC 
treated water before use). Labelled probe was then added to the pre-hybridisation 
buffer and incubated at 42°C overnight.
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2.6.5 Molecular Probes
Probes were generated by random priming using a-^^P-dCTP.
WAF-1 : This 12.4 kb cDNA fragment was used for Northern blotting and was 
derived from the plasmid, pCEP-WAF-l-S (30). The template was obtained from 
Margaret Caimey and had been prepared by digestion of the plasmid, using the 
appropriate restriction enzyme i.e. Notl.
GAPDH : Probe was generated by digestion with EcoRI and obtained from Liam 
Gallagher.
2.6.6 Washing Membranes
Following formamide hybridisation, membranes were washed at room temperature 
for 15 miutes in lxSSPE and 0.5% SDS, followed by a 1 hour wash in 0.5xSSPE / 
0.5% SDS at 65°C. The final wash in O.lxSSPE / 0.5% SDS was carried out for 
approximately 30 minutes at 65°C.
2.6.7 Autoradiography
Following washing, filters were blotted dry, wrapped in clingfilm and exposed to 
Kodak AR film in a film cassette with fast tungstate intensifying screens. Loaded 
film cassettes were held at -70°C until developed.
2.7 Microbiological Techniques
2.7.1 Bacterial Culture
Bacteria were maintained on Luria agar (1.5% agar in L-broth) plates at 4°C. 
Ligations were maintained as described, with the addition of 40pl X-gal (20mgml" 
1) and 8pi IPTG (lOOmgml'l). Bacteria were stored for long periods in 15% 
glycerol in L-broth (1% tryptone, 0.5% yeast extract, 1% NaCl) at -70°C.
45
2.7.2 Transformation Of Bacterial Cultures With Plasmid
DNA
50jj.1 of competent bacteria were added to 1-1 Ong of transforming DNA. The
protocols provided with each cell strain were followed. Cells were grown 
overnight at 37°C on appropriate selection media and picked, using sterile Gilson 
pipette tips, into 10ml or 5ml of LB medium containing lOOmgml'l ampicillin for 
plasmid retrieval using the Qiagen Maxi Preparation kit and the Flowgen SpinBind 
procedure respectively.
2.7.3 Recovery Of Plasmid DNA From Bacterial Cultures
5ml of a 10ml culture was used to innoculate 500ml of L-broth containing 
lOOmgml'l ampicillin (for selection) and this culture was grown to stationary 
phase overnight. The Qiagen Maxi Preparation kit was used according to 
manufacturers recommendations to obtain plasmid DNA. The second 
centrifugation (step 5) was replaced by filtration through Whatman 3MM paper. 
Alternatively, plasmids were purified from 4.5ml of a 5ml culture using the 
Flowgen SpinBind protocol.
2.8 Plasmid Manipulations
2.8.1 Restriction Digests
Restriction digests were carried out according to manufacturer’s instructions, with 
the total enzyme concentration in the reaction not exceeding 10%. Double digests 
were performed using HindlW and Clal in the same reaction using REactI as the 
buffer. To compensate for the low activity of HindlW in this buffer i.e. -30%, 
three times the number of recommended units of HindlW were used. Reactions 
were carried out at 37°C for 2-6 hours.
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2.8.2 De-Phosphoiylation Reactions
De-phosphorylation of restriction digested plasmids were performed with CIP (calf 
intestinal phosphatase). The protocol detailed in Sambrook et al. (99) suggests the 
use of 1 unit of CIP per lOOpmoles of DNA, however CIP was used in excess of 
this concentration. A standard phenol chloroform DNA extraction was performed 
to isolate digested plasmid DNA. DNA was precipitated with 2.5 volumes of 
ethanol and resuspended in 90pl of lOmM Tris'HCl pH8.3. lOx CIP buffer was 
added to a final concentration of lx, and the appropriate volume of CIP enzyme 
was added. After an incubation at 37°C for at least 30 minutes, SDS and EDTA 
pH8 were added to final concentrations of 0.5% and 5mM respectively. 
Incubation in this mixture at 56°C for 30 minutes is sufficient to inactivate the 
phosphatase. Following cooling to room temperature, DNA was extracted once 
with phenol at room temperature and once with phenol /  chloroform at 4°C. DNA 
was precipitated as detailed in 2.3.2 and the pellet was resuspended in TE and 
stored at -20°C.
2.8.3 Ligation Reactions
Ligation reactions were carried out in a final volume of no greater than lOpl so as 
to maintain a high concentration of 5' and 3’ DNA ends. The reactions were 
performed using an excess of the insert (~10x) in lx ligase buffer in the presence of 
lOpgpl'1 BSA and incubated overnight at room temperature. The ligated products 
were used to transform DH5a sub-cloning efficiency competent cells as described 
in manufacturer’s instructions. The transformants were selected on Luria agar 
plates using ampicillin, X-gal and IPTG (see section 2.7.1) incubated overnight at 
37°C. The plates were left at 4°C for approximately 4 hours to allow the blue 
colour in the colonies to develop, then white colonies were picked, cultured and 
plasmid DNA purified as described in section 2.7.3. Blue colonies were treated in 
the same way as a comparison.
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Chapter 3 : Results
3.1 Introduction
Fifteen putative cisplatin genetic suppresser elements (GSE’s) had previously 
been isolated by Kirschling et al. (94) from a pool of cDNA fragments derived 
from a DNasel digestion of a normalised HeLa cDNA library. In order to confirm 
that these GSE's confer cisplatin resistance we have transfected them, expressed in 
the pLNCX vector, into the A2780 human ovarian adenocarcinoma cell line and 
examined the transfectants by clonogenic assay. The experimental results detailed 
here confirm that resistance to cisplatin is conferred by several of these GSE’s. 
Cisplatin is thought to exert its cytotoxic effects as a consequence of its DNA- 
damaging activity. I was interested to determine whether GSE-induced cisplatin 
resistance was a result of interference within a DNA-damage response pathway 
common to more than one DNA damage-inducing agent. To investigate the 
possibility of a multi-agent resistant phenotype, resistance to y radiation was 
assessed again by clonogenic assay.
PCR amplification of GSE DNA and DNA sequencing were used to verify the 
presence of the GSE DNA and so validate the results of the resistance analyses, as 
well as confirming the genomic origin of the DNA.
Many agents which induce DNA damage have been shown to result in cell cycle 
arrest checkpoints (10). I was interested to examine the checkpoint phenotypes, in 
response to DNA damage in the GSE transfectants and so carried out an analysis 
of Gl/S and G2/M checkpoints in response to ionising radiation and cisplatin 
One pathway which is thought to be important in the response to DNA damage is 
the p53 / waf-1 mechanism (fig. 1.3.2). I was interested to determine whether it is 
this pathway which the GSE's are interfering in and so analysed waf-1 RNA levels 
using a Northern analysis approach.
49
3.2 Resistance to Cisplatin
The GSE’s which were used to transfect the A2780 cell line were all originally 
isolated as a consequence of conferring cisplatin resistance to HeLa and / or 
HT1080 cell lines. The lines generated by transfection of GSE 7.10 into the 
A2780 cell line are shown in table 3.2.1 along with descriptions of other cell lines 
used. Unless otherwise noted, the transfected lines represent geneticin resistant 
colonies pooled after DNA transfection and selection for the GSE shown.
CELL LINE DESCRIPTION
A2780 Parental cell line
A2.9 LNCX vector alone
A2.14 GSE 7.10
A2.14.53 GSE 7.10
A2.14.93 GSE 7.10
A2.14.103 GSE 7.10
A2.22 GSE 7.10
A2.15 GSE 7.1
A2.23 GSE 7.1
A2.16 GSE E4
A2.24 GSE E4
53.1.6 V i4 3 ~>A dominant negative p53 mutant
3 denotes a subclone o f  the A 2 .14 cell line
Table 3.2.1 Description of the cell lines examined in the resistance (and 
other) experiments.
The resistance to cisplatin of the GSE transfectants compared with the parental 
A2780 line and the pLNCX transfected control line A2.9, was examined by 
clonogenic survival assay. The resistance values were calculated by dividing the 
surviving fraction (s.f.) after cisplatin treatment of the transfectants with either
50
A2780 s.f. values or the vector alone transfectants, A2.9. The plating efficiency 
of each line is also recorded. The results of a 24 hour exposure to lpM cisplatin 
are detailed in table 3.2.2.
CELL
LINE
GSE PLATING
EFFICIENCY
MEAN 
SURVIVING 
FRACTION (a)
STANDARD
ERROR
MEAN
RESISTANCE
A2780 none 30% 0.15(12) 0.007 1
A2.9 pLNCX 54% 0.15(2) ND 1
A2.22 7.10 34% 0.43 (8) 0.025 2.9
A2.15 7.1 38% 0.25 (6) 0.021 1.7
A2.23 7.1 12% 0.22 (8) 0.042 1.5
A2.16 E4 11% 0.25 (8) 0.03 1.7
(a) Surviving fraction in relation to untreated controls. Numbers in parenthesis represent 
the number of experiments, plating 1(P cells per experiment.
Table 3.2.2 Results of clonogenic survival assays after a 24 hour exposure 
to lpM  cisplatin.
All of the lines examined show a degree of resistance to cisplatin treatment with 
the A2.22 cell line showing the highest levels i.e. 2-3.8 fold resistance compared 
with the A2780 and A2.9 cell lines.
The sensitivities of the GSE transfectants to a one hour exposure to 20pM 
cisplatin was examined and the results shown below.
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CELL
LINE
GSE PLATING
EFFICIENCY
MEAN
SURVIVING
FRACTION
(a)
STANDARD
ERROR
MEAN 
RESISTANCE 
COMPARED 
WITH A2.9
A2.9 pLNCX 29% 0.012 (12) 0.004 1
53.1.6 none 32% 0.03 (4) 0.003 2.5
A2.22 7.10 50% 0.071 (12) 0.015 5.9
A2.14 II 17% 0.024 (12) 0.009 2
A2.14.10 II 21% 0.093 (4) 0.01 7.8
(a) Surviving fraction in relation to untreated controls. Numbers in parenthesis represent the 
number of experiments, plating 103 cells per experiment.
Table 3.2.3 Results of clonogenic survival assays after a one hour
exposure to 20pM cisplatin. The response of a line 
transfected with a dominant negative mutation of p53, 53.1.6, is also shown 
for comparison.
These clonogenic assays show that the lines generated by transfection of GSE 7.10 
into the A2780 cell line exhibit an increased resistance to a 1 hour exposure to 
20pM cisplatin as well as the resistance observed in response to a 24 hour 
exposure to lpM cisplatin. It is interesting to note that the subclone of A2.14, 
A2.14.10, has a resistance factor higher than that of both A2.14 and A2.22. This 
may reflect a highly resistant sub-population of transfectants from the population 
of cisplatin selected A2.14 cells. For instance, this may represent a sub­
population of cells which highly express the GSE and will uniformly express the 
GSE in clonal isolates.
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3.3 Resistance to Ionising Radiation
Clonogenic assays were used to determine the levels of resistance of the GSE 
transfectants to 2 Grays ionising radiation compared with the pLNCX transfected 
control line A2.9. The resistance values were calculated by expressing the 
surviving fraction (s.f.) of the A2.9 cell line at 2 Gy as 1.0 and comparing the s.f. 
values of the other lines to this. The plating efficiencies have also been 
i  determined, and are comparable between the transfected lines. The results of the
j
clonogenic assays are summarised in table 3.3.1.
The results of these assays suggest that several of the GSE 7.10 transfectants have 
an increased resistance to ionising radiation compared with the control cell line 
generated by transfection of the pLNCX vector alone. As in the previous 
experiments using cisplatin, the A2.22 cell line appears to confer the most 
significant level of resistance to treatment with a DNA damaging agent. For this 
reason I have concentrated on the analysis of the cell lines generated by 
transfection of GSE 7.10 into the A2780 cell line i.e. A2.22 and A2.14 and its 
subclones.
The resistance of the GSE transfectants was also compared with the A2780 
parental cell line following treatment with ionising radiation. The results of these 
assays were ambiguous as a result of abnormally high levels of resistance in this 
batch of cells. Other procedures in the laboratory gave anomolous results with this 
stock of A2780 cells which have subsequently been discarded. Consequently, 
confirmation of the radio-resistance results compared with the A2780 cell line will 
be required.
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CELL
LINE
GSE PLATING
EFFICIENCY
MEAN
SURVIVING
FRACTION
(a)
STANDARD
ERROR
MEAN 
RESISTANCE 
COMPARED 
WITH A2.9
A2.9 pLNCX 27% 0.034 (4) 0.014 1
A2.14 7.10 13% 0.11 (4) 0.025 3.2
A2.14.9 II 20% 0.083 (3) 0.033 2.4
A2.14.10 II 20% 0.177(4) 0.018 5.2
A2.22 II 35% 0.243 (4) 0.026 7.1
(a) Surviving fraction in relation to untreated controls. Numbers in parenthesis represent 
the number of experiments, plating 10  ^ cells per experiment.
Table 3.3.1 Results of clonogenic assays after exposure to 2 Gy ionising 
radiation.
3.4 PCR Amplification Of GSE 7.10 From A2.14
And A2.22
PCR amplification was employed to verify that the GSE DNA was still present 
within the GSE 7.10 transfectants. To carry out molecular analyses, DNA was 
extracted from the cell lines transfected with GSE 7.10 i.e. A2.14 and A2.22 as 
well as from vector alone transfectants, A2.9 and the parental cell line, A2780. 
The presence of DNA was confirmed by gel electrophoresis and the concentration 
determined by spectrophotometry.
Details of the primer binding sites are shown in fig. 3.4.1. The primers are 
complimentary to sequences within the pLNCX vector which flank the GSE 
insertion site, so amplification of the insert and flanking vector sequences would 
be expected. To ensure that the amplification process was specific, DNA from the 
A2780 parental cell line was treated in the same way as the transfectants. The
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RNA
►
C M V  /adaptors 
p ro m / ^
LTRLTR neo
c D N A
insert
GGACCTCTGCGGTAGGTGCGACAAAACTGGAGGTATC TTC TGTGGCCCTGGCTAGGTCGGAGGCGCCG  
CCTGGAGACGCCATCCA CGCTGTTTT GACCTCCA TAGAAG ACACCGGGACCGATCCAG CCTCC GCGGC
Prim er C
H indlll
GGG TTC GAA TACCTACCTAC 
CCC AAGCTT ATGGATGGATG 
start
CTu I
A C T C A C T C A C T T  A G C T A T T T T A G G G G  
t g a G  t g a G  TGAA T C G A T l A A A A T C C  C C
stop stop stop
Primer I)
C TA AAC AG AG G TC TTTTTCC CCC CTTCTTTC TG G G G TG A C ATCC AAA CCG TT C GAT CGA 
GATT TGT C T CCAGAAAAAGGGGGGAAGAAAGACC C CAC TG TAG G TTTG GCAAG  CTAGCT
Figure 3.4.1 Diagram of the pLNCX vector detailing relevent 
restriction sites and primer binding sites
pLNCX^-10 plasmid was also amplified to act as a marker in the agarose gel 
analysis.
The photograph in fig. 3.4.2 shows the electrophoretic separation of the PCR 
products obtained. Amplification of the two negative controls i.e. A2780 DNA 
template and water, did not result in any product being generated, so amplification 
of the other samples can be presumed to be specific. The pLNCX^lO plasmid 
amplified to give a product of approximately 300bp as did the DNA extracted from 
the GSE 7.10 transfectants, A2.14 and A2.22. This suggests that the same 
fragment of DNA has been amplified in all three cases, indicating that the 
pLNCX^-lO plasmid is still present in the transfectants. DNA from the A2.9 line, 
which has been transfected with the pLNCX plasmid without a GSE insert, yielded 
a product in the region of lOObp, suggesting that GSE7.10 is approximately 200bp. 
The intensely stained smears at the foot of the gel are the result of primer 
dimerisation.
3.5 Sequencing To Confirm Identity of GSE 7.10
GSE 7.10 had been identified by Kirschling et al. (94) to be a fragment of the 
human phosphoglycerate mutase B gene (PGAM-B), acting in a sense orientation. 
In order to confirm the identity of the PCR amplified DNA, the PCR products 
obtained from the A2.14 and A2.22 cell lines were purified and prepared for DNA 
sequence analysis. The sequences obtained were entered into the GenBank™ 
/EMBL DNA sequence database and the search confirmed that the PCR products 
are 100% identical to a 188 base pair fragment of the human phosphogly cerate 
mutase-B (PGAM-B) gene (fig. 3.5.1) (101).
PGAM-B is a glycolytic enzyme which catalyses the conversion of 3- 
phosphoglycerate to 2-phosphoglycerate using 2,3 bisphosphoglycerate as a 
cofactor. It is highly conserved from yeast through to man and a homologous
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Figure 3.4.2 Gel showing the results of the PCR amplification 
of total DNA isolated from A2.22, A2.14, A2.9 and 
A2780 using primers complementary to 
sequences of the LNCX plasmid vector. Controls 
are water and the LNCX vector incorporating 
GSE 7.10. (MW = 123bp DNA ladder)
30 40 50 60 70 80
G S E 7 . 1 0  CGGCCCCCNCAAACATCGATGGATGGATGGCAGCTACCCTCCTGTGAGAGTCTGAAGGAT
I I I I I I I I I I I I I I I I I I I I I I I II  I I I I I
PGAM-B GAT CGCAGGTAT GCAGACCT CACAGAAGAT CAGCTACCCTCCT GTGAGAGTCT GAAGGAT
450 460 470  480  490 500
90 100 110 120 130 140
G S E 7 . 1 0  ACTATTGCCAGAGCTCTGCCCTTCTGGAATGAAGAAATAGTTCCCCAGATCAAGGAGGGG
I I I II I I I I I  I II I I II I II I I I I I I II I I I I II I I II I II II I I II I I I II I I I I I II I
PGAM-B ACTATTGCCAGAGCTCTGCCCTTCTGGAATGAAGAAATAGTTCCCCAGATCAAGGAGGGG 
510 520 530 540 550 560
150 160 170 180 190 200
G S E 7 . 1 0  AAACGTGTACTGATTGCAGCC£ATGGCAACAGCCTCCGGGGCATTGTCAAGCATCTGGAG
I I I I I I I I I I I I I I I I M I I I I I I I l l l l l l l l l l I I I l l l l l l l  l l l l l l l l  l l l l l l l
PGAM-B AAACGTGTACTGATTGCAGCCCATGGCAACAGCCTCCGGGGCATTGTCAAGCATCTGGAG 
570 580 590 600 610 620
210 220  230  240 250 260
G S E 7 . 1 0  GGTCTCTCTGAAGAGGCTATCATGGAGCTGAAACCTGCCCCATCCATCCATCGAAAAAAT
I I I II I I I I I II I II I I I I I II  II I I I I I I I I I I I I II I
PGAM-B GGTCTCTCTGAAGAGGCTATCATGGAGCTGAACCTGCCGACTGGTATTCCCATTGTCTAT 
630 640 650  660 670 680
Figure 3.5.1 DNA sequence alignment of GSE 7.10 with human
phosphoglycerate mutase B (accession no. J04173). The GSE 
was isolated by PCR from both the A2.14 and A2.22 cell lines (see section 3.4 
and 3.5). The highlighted bases represent the codon for the histidine residue 
(His 181) of the active site of the enzyme.
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enzyme has also been identified in bacteria. At least two isoforms of the enzyme 
exist in man, one is muscle-specific, the M isoform, and another is non-muscle- 
specific, the B isoform. The enzyme is thought to act as a dimer and has not 
previously been linked to any form of drug resistance.
3.6 Subcloning of A2.14
The ionising radiation and cisplatin resistance experiments described previously 
suggest that one of the two independently GSE 7.10-transfected cell lines, A2.22, 
has a greater level of resistance than the other i.e. A2.14. When viewed by light 
microscopy, the gross morphology of these two transfected lines differed 
significantly. The A2.22 cells are homogeneously small and rounded, whereas the 
A2.14 cell line is more heterogeneous, in that both small rounded cells and larger, 
more flattened cells are present within the same population. I was interested to 
investigate whether the two morphologically different populations of the A2.14 
displayed different characteristics in terms of their resistance to DNA damaging 
agents, and whether this resulted in the population as a whole, having a less 
dramatic phenotype than the A2.22 cell line.
In an attempt to isolate these two morphological populations within the A2.14 line, 
cells were grown and colonies were picked and expanded. All of the colonies 
however contained cells of both morphologies and so it proved impossible to 
segregate the cells on this basis. Three clones were maintained for further 
investigations and were designated A2.14.5, A2.14.9 and A2.14.10.
59
3.7 Cell Cycle Arrest Assay
Many DNA damaging agents have been shown to induce cell cycle checkpoint 
arrests. In order to assess any effect on cell cycle checkpoints which the GSE’s 
were exerting, an assay to determine the percentage of cells in each phase of the 
cell cycle in response to cisplatin and ionising radiation treatment was carried out. 
Both agents cause DNA damage correlating with an arrest at the Gl/S and G2/M 
checkpoints! (102, 21, 44). This assay therefore assesses the ability of the GSE 
transfectants to block DNA replication and mitosis in response to DNA damaging 
agents. Wild-type cell cycle distribution is determined by analysing untreated 
cells, and this data is used as a comparison.
The cell cycle assay relies on the detection of a fluorescent antibody which binds 
the DNA replication-positive marker, 5-bromodeoxyuridine (BrdU) and the 
fluorescent activity of propidium iodide (PDI), a DNA intercalating agent. The 
staining achieved is therefore an accurate indicator of DNA replication and DNA 
content i.e. 2n and 4n. Table 3.7.1 describes the BrdU status and DNA content 
expected for each cell cycle phase.
The assay is performed on asynchronous cells grown in culture, and the results 
assessed by FACS (Fluorescence Activated Cell Sorting) analysis. The cells are 
sorted into separate populations as a result of differences in fluorescent staining 
and counted. Typical examples of the data produced are shown in figs. 3.7.1 and 
3.7.2.
The numerical data generated by histogram B is used to calculate the percentage 
of treated cells in the Gl, S and G2 phases of the cell cycle compared with the 
percentage of untreated cells in each phase. For example, if examining the ability 
of the cells to block DNA replication in response to DNA damage, the percentage 
of cells in S-phase is calculated with respect to the percentage of untreated cells in 
S-phase. The result is therefore a measurement of the incorporation of BrdU into 
DNA. In theory, for cells which are capable of blocking
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Figure 3.7.1 Example of results of cell cycle FACS analysis. The histograms 
represent a population of untreated cells which have been pulsed with BrdU and 
stained with propidium iodide (PDI) prior to analysis.
FL1-H  : Represents BrdU staining e.g. histogram D represents the number o f cells (y- 
axis) emitting any particular intensity o f fluorescence generated by binding o f  the FITC 
conjugated antibody to BrdU. FL2-H : Represents PDI staining e.g.histogram B 
classifies each cell in terms o f its BrdU (x-axis) and PDI (y-axis) content. FL2-W  : 
Represents a measurement o f cell size. This reading allows the exclusion from the 
analysis o f cell aggregates (see histogram A).
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Figure 3.7.2 Example of results of cell cycle FACS analysis. The histograms 
represent a population of cells which were pulsed with BrdU and stained with PDI 
following a one hour incubation with 20p.M cisplatin.
When the histograms for these treated cells are compared with those for the untreated 
cells, then it is clear that there has been a large reduction in the proportion o f cells in S 
phase following cisplatin treatment. This is seen in both histograms B and D, where the 
shift from BrdU+ cells to BrdU- cells is clear. One can conclude therefore that the
cisplatin treated cells have arrested at the G1 checkpoint, thus preventing progression to 
the S phase o f the cell cycle where DNA replication would occur.
CELL CYCLE 
PHASE
BrdU
STATUS
DNA CONTENT 
(propidium iodide 
staining)
G1
—
2n
S + 2n-»4n
G2 + 4n
M + 4n —» 2n
Table 3.7.1 BrdU status and DNA content of cell cycle phases.
entry into S-phase and so blocking DNA replication, the resultant value would 
approach zero, whereas those cells unable to arrest at this checkpoint would have a 
value for BrdU incorporation approaching 100%. In reality, in the A2780 cell line, 
a value of 20 - 40% is consistent with a population of cells with a functional G1 / S 
arrest, and so a value in excess of this indicates continuation of DNA replication 
following genotoxic insult.
Staining is carried out at 3 time points after the DNA damaging treatment, 6 hours 
to examine the G2 checkpoint, 24 hours for the G1 checkpoint and also at 48 
hours.
The controls used in these assays were the parental line, A2780, and / or the vector 
alone transfectant, A2.9. The 53.1.6 line was also assessed. This line has been 
transfected with a dominant negative mutant of p53 (codonl43 val->ala) and has 
been extensively shown, in this laboratory, to have lost its capability to arrest at the 
G1 to S-phase checkpoint in response to ionising radiation and cisplatin (44). 
Unpublished data also suggests that this line is incapable of arresting at the G2 to 
M checkpoint in response to cisplatin treatment.
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3.7.1 Ionising Radiation Induced Cell Cycle Arrests
Six of the GSE transfected cell lines were examined in terms of their response to 
ionising y radiation. The results of these assays are shown in fig.3.7.3 and 3.7.4 
and usually represent 3 samples of treated and untreated cell populations.
The controls in the experiment shown in fig.3.7.3 were the A2780 parental line 
(A) and the A2.9 vector alone transfectant line (■). Both of these lines were 
expected to exhibit a functional Gl/S phase checkpoint arrest in response to 
ionising radiation. The data shows that this is the case for the A2780 and A2.9 
cell lines i.e. at the 24 hour time-point, the percentage of these cells able to 
incorporate BrdU into their DNA has decreased by 50-60% compared with 
untreated cells. The other control line is 53.1.6 (•). This has been transfected 
with a dominant negative mutant of p53 and as a result, the cell cycle arrest 
potential of this line is severely compromised (44). The results confirm that this is 
the case as there is a reduction of only 35% in the number of actively cycling cells 
post-radiation. As expected, the maximal reduction in the percentage of cells in S 
phase is seen 24 hours after radiation. This is consistent with previous data (44). 
Of the GSE transfectants analysed here, at least two show a severely compromised 
ability to arrest at the Gl/S checkpoint in response to ionising radiation as 
measured by a reduction in BrdU incorporation.
The A2.22 line (□), which has been transfected with GSE 7.10 exhibits the least 
reduction in the percentage of BrdU+ cells following exposure to ionising 
radiation, and is striking in that the percentage of actively cycling cells at the Gl/S 
transition 24 hours after treatment is greater than the 53.1.6 (mutant p53) line. 
The line generated by an independent transfection of GSE 7.10, A2.14 (A), shows 
less of a reduction in BrdU+ cells than the vector alone control line.
The A2.23 line (o), which has been transfected with GSE 7.1 has a reduction in 
G1 arrest in response to y radiation. At the 24 hour time point, this line has a 
reduction of approximately 35% in the number of actively cycling cells, a value 
similar to that for the 53.1.6 cell line. The other line examined in this experiment
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Figure 3.7.3 Graph details the results of FACS analysis,
showing the percentage of BrdU positive
GSE transfectants following treatment with 
2Gy ionising radiation
is the A2.24 line, which has been transfected with GSE E4. This line appears to 
have a functional arrest, in that approximately 60% of cells are arrested at 24 hours 
post-treatment, a value similar to that for the A2.9 and A2780 control lines.
To confirm the results described above, i.e. that the GSE 7.10 transfectants, A2.14 
and A2.22 have a reduced capability to undergo G1 arrest in response to ionising 
radiation, the experiment was repeated. The values recorded at the 24 hour time 
point are shown below.
CELL LINE A2780 A2.9 53.1.6 A2.14 A2.22
MEAN % BrdU+ CELLS 38.6 49.3 69.7 47.5 75.9
STANDARD ERROR 0.96 5.80 10.68 0.55 0.95
SAMPLE NUMBER 3 3 3 3 4
Table 3.7.2 Mean % values of BrdU+ cells 24 hours after exposure to 2Gy 
ionising radiation. This describes the percentage of treated 
cells which are still actively cycling through the G l/S checkpoint
As in the previous experiments, the A2780 and A2.9 lines show a decrease in 
actively cycling, BrdU+ cells of greater than 50%, whereas the 53.1.6 mutant p53 
transfectants show only a limited reduction in the percentage of BrdU+ cells after 
treatment at 2Gy. The A2.22 line shows a very limited reduction in BrdU+ cells, 
that is, only 24%. This supports the initial data that the transfected GSE is 
exerting a cell cycle effect i.e. a reduction in the capability to arrest at the G1 
checkpoint after exposure to ionising radiation. The A2.14 cell line appears to act 
in a wild-type manner with respect to a G1 arrest in this experiment, having a 
greater than 50% reduction in cells actively synthesising DNA.
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Fig. 3.7.4 shows the results of an additional experiment, examining the cell cycle of 
the A2.15 and A2.16 lines in response to ionising radiation. These lines have been 
transfected with GSE 7.1 and E4 respectively. In this experiment, the control lines 
do not exhibit the extreme differences which would be expected. The 53.1.6 
mutant p53 transfectant has 70 % of cells able to incorporate BrdU into their DNA 
in response to ionising radiation, indicating a loss of G1 arrest. The A2.9 line 
however also has a large percentage of cycling cells after treatment, approximately 
60%. The low level of reduction in the percentage of BrdU+ cells in the A2.9 line 
makes the data generated from the GSE transfectants difficult to interpret. Both 
transfectants have a greater reduction in the percentage of BrdU+ cells than either 
the A2.9 or 53.1.6 cell lines. The indication is therefore that the two GSE 
transfected lines have a functional G1 arrest in response to ionising radiation.
The percentage of cells with a 4n DNA content was also measured to determine 
the G2 arrest phenotypes. The data is not shown as all lines exhibited a strong 
G2/M checkpoint arrest in response to ionising radiation.
In conclusion, these experiments show that transfection of at least two of the 
GSE's into the A2780 cell line i.e. GSE 7.10 and GSE 7.1 results in an abnormal 
response to ionising radiation in terms of the ability of the cells to incorporate 
BrdU into their DNA. This suggests that these transfectants are able to continue 
replicating their DNA following damage, that is, they have a reduced capacity to 
arrest at the G1 / S checkpoint. GSE 7.10 is of particular interest as A2.22 (a line 
generated by transfection of GSE 7.10) shows the most extreme loss of G1 arrest, 
comparable to that of a line containing functionally mutant p53, and the A2.14 line 
which was generated by an independent transfection of the same GSE also exhibits 
a compromised G1 arrest phenotype.
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3.7.2 Cisplatin Induced Cell Cycle Arrests
G1 Arrest
Figure 3.7.5 shows the G1 arrest data in response to a 20pM cisplatin exposure 
over a one hour time period. The results usually represent 3 samples of treated 
and untreated cell populations.
The A2.9 vector alone control line (■) shows a reduction in the percentage of 
BrdU"1" cells at 24 hours of less than 20%. This is a surprising result as this line 
should exhibit an arrest at the G1 / S checkpoint in response to cisplatin treatment. 
The reduction of BrdU+ cells at 48 hours is significantly greater, i.e. 
approximately 80%. The cell line generated by transfection of the A2780 cell line 
with a dominant negative mutant of p53, 53.1.6, (•) has previously been shown to 
have lost its ability to arrest at the G1 checkpoint in response to DNA damaging 
agents. Consistent with these observations, the 53.1.6 cell line has a reduction in 
BrdU+ cells of 10% at 24 hours. This reduction does continue to the 48 hour time 
point, but the reduction is less than for the A2.9 control line.
Of the three GSE transfected lines (all with GSE 7.10) two, A2.14 (A) and A2.22 ( 
□), have no reduction in the percentage of BrdU+ cells at 24 hours. This suggests 
that both of these lines are capable of continuing DNA replication after cisplatin 
treatment, that is, they do not arrest at the G1 / S checkpoint. The sub-clone of 
A2.14, A2.14.5 (o), showed a wild-type arrest phenotype. The phenotypes at 48 
hours were unusual when compared to previous experiments in this group as the 
percentage of BrdU+ cells would be expected to rise. The absence of this may be 
due to nutrient depletion of the culture medium.
From this data, it appears that the GSE 7.10 transfectants, A2.14 and A2.22 have a 
decreased ability to arrest at the G1 checkpoint in response to treatment with the 
DNA damaging agent cisplatin. The sub-clone of A2.14, A2.14.5, appears to have 
a wild-type arrest in these conditions. It should be noted that this clonal 
population has not had the presence of GSE 7.10 confirmed by PCR amplification.
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Figure 3.7.5 Graph details the results of FACS analysis,
showing the percentage of BrdU positive
GSE transfectants following treatment with 
20uM cisplatin
The A2.9 vector alone control line used in this assay does not however conform to 
the expected wild-type arrest phenotype expected. The results of this assay 
therefore require confirmation.
G2 Arrest
Cisplatin has previously been shown to induce cell cycle arrest at the G2/M 
| checkpoint as well as at Gl/S (102, 21). Figure 3.7.6 shows the data relating to 
G2 arrest as determined by the percentage of cells with a 4n DNA content. The 
results usually represent 3 samples of treated and untreated cell populations.
The ability to arrest at the G2 checkpoint is assessed at the 6 hour time point. At 
the 6 hour time point, the GSE transfectants showed moderate changes in the 
percentage of cells containing 4n DNA. As can be seen in fig. 3.7.6, the more 
dramatic changes in the 4n DNA population occurred at 24 hours. At this stage, 
the vector alone control line, A2.9 (■), showed a large increase in the percentage 
of 4n cells, approximately 10-fold greater than at time = 0. In comparison, the 
53.1.6 mutant p53 cell line (•) showed only a 4-fold increase in the percentage of 
cells with a 4n DNA content by 24 hours. This value decreased rapidly from 24 to 
48 hours, whereas the A2.9 line maintained its arrest towards the 48 hour time 
point.
The GSE transfected cell lines displayed a phenotype intermediate between these 
two extremes. The A2.22 line (□) had approximately a 6-fold increase in 4n cells 
by 24 hours which fell off slightly by 48 hours. A2.14.5 (o) had a 4-fold increase 
in 4n cells by 24 hours, and this value continued to rise towards 48 hours. A2.14 ( 
A) had only a 2-fold increase in 4n cells by 24 hours and a 5-fold increase at 48 
hours. | These results suggest that the GSE 7.10 transfectants show a reduction in their 
G2/M arrest capability when compared to a pLNCX transfected vector alone 
control line. This reduction in cells with a 4n DNA content occurs at the 24 hour 
time-point rather than at 6 hours after treatment with cisplatin and does not 
represent a reduction to the level seen in the dominant negative mutant p53
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transfectants. Consequently, this data requires clarification in order to determine 
whether the reduction in the percentage of cells with a 4n DNA content is 
significant.
The doubling time of the cell lines examined in the cell cycle arrest assays should 
also be determined. This will confirm that the presence or absence of cell cycle 
arrests is not an artefact due to a change in doubling time resulting from the 
transfection procedure.
3.8 Northern Blotting To Examine waf-1 RNA Levels
Waf-l expression is induced by elevated levels of p53 protein in response to DNA 
damage (30), therefore the level of waf-1 RNA is an indication of p53 
transactivation activity. In order to determine whether the p53/waf-l pathway is 
being interfered with by transfection of GSE 7.10, waf-1 RNA levels have been 
estimated in the GSE 7.10 transfectants by Northern blot analysis. Figure 3.8.1a 
shows the waf-1 RNA levels in the GSE 7.10 transfectants as well as the parental 
cell line, A2780, and the vector alone transfectant, A2.9. Also examined was a 
line sub-cloned from A2.14, A2.14.5, and A2780cp70, a cisplatin resistant 
derivative of the parental A2780 cell line, which exhibits a marked reduction in 
p53 activity and would therefore be expected to have reduced levels of waf-1 
RNA. The lower autoradiograph shows the hybridisation with a GAPDH probe, 
used in order to take account of the initial loading amount of RNA.
The graph in figure 3.8.1b shows the relative densities of the waf-1 hybridisation 
signals in the various lines tested. The RNA loading levels were corrected using 
the GAPDH signals in the same lines using the autoradiographs shown in fig. 
3.8.1a. The maximum fold difference between the lines is low enough to indicate 
that there is no significant difference in waf-1 RNA levels between the samples. It 
would be expected that the A2780cp70 cell line would have a reduction in the 
levels of waf-1 RNA as it lacks functional p53 and has been confirmed previously.
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3.9 Tetracycline Inducible System
In order to confirm that the transfection of GSE 7.10 is responsible for the 
phenotypic effects described, an inducible gene expression system based on 
tetracycline responsive elements (95) is being developed. This system is used in 
preference to other inducible systems due to its reported efficiency as a very clean 
on/off switch. Many other inducible systems can 'leak', that is, a low level of 
constitutive expression occurs as the element or molecule which is used as the 
switch is endogenous to the cell line in use, for example, the metallothionein and 
dexamethasone systems.
The tetracycline system requires the use of two plasmids, one which incorporates 
the transactivator construct, the other carries the tetracycline operator sequence. 
The transactivator consists of the tet-repressor sequence from E.coli fused to 
VP 16 the herpes virus transactivator. This construct acts as a transcription factor, 
the target of which is a minimal eukaryotic promoter with a series of tet-operator 
sequences and the gene of interest. In the presence of tetracycline, the 
transactivator binds to tetracycline and so is prevented from binding to the 
operator sequences. As a result, the gene of interest is not transcribed. When 
tetracycline is removed, the transactivator is free to bind the operator sequence 
j  and transcription of the gene (or GSE) of interest results.
The work detailed here describes only the initial steps carried out in the generation 
of this system.
3.9.1 pUH Plasmid Purification
The plasmid constructs for use in the tetracycline inducible system are described 
in section 2.1.4 and were obtained from H. Bujard (95). The plasmids were 
rehydrated as instructed and used to transform Epicurian Coli SURE competent 
cells according to the manufacturer’s instructions. Plasmid DNA was purified
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using the Qiagen maxi prep, protocol. Diagnostic restriction digests were 
performed to ensure that the constructs were intact as expected.
3.9.2 Transfection
Transfection of the tetracycline transactivation complex tTA was achieved using 
the calcium phosphate technique. The pUHD15-l plasmid was co-transfected into 
a resistant derivative of the A2780 cell line, A2780cp70 and also into the MCF-7 
cell line with a neomycin resistance marker plasmid as detailed:- 
• 20|ig / lOpig plasmid DNA, pUHD15-l along with 4pg / 2 i^g G418 resistance
marker plasmid ZIPneoSV(X)l or pSVneo.
The colonies were selected with G418 and picked into 24-well plates and 
expanded into tissue culture flasks. Resistant colonies have been frozen for 
storage at -70°C.
Approximately 50% of the A2780cp70 transfectants (pSVneo + pUHD15-l) 
which were picked into the 24-well plate were viable. None of the MCF-7 
colonies grew once transferred into the 24-well plates. These observations appear 
to be independent of original size of colony, time at which they were picked and 
neomycin resistance marker plasmid used. Control cells (MCF-7 and A2780cp70) 
were transfected with salmon sperm DNA and resistant colonies developed on the 
master plates. However, these were not picked into 24-well plates so the 
explanation for the low / zero viability of the pUHD15-l transfectants is 
unknown. Both of these cell lines have previously been transfected successfully, 
so an inherent cellular problem is unlikely.
In the absence of tetracycline, this inducible system is switched on. It is possible 
in these transfection conditions that the pUHD15-l plasmid is toxic at its site of 
integration. As a result, the transfections were repeated in the presence of 
tetracycline as well as G418, the rationale being that the presence of tetracycline 
prevents transcriptional activation. In both the presence and absence of 
tetracycline, resistant colonies of A2780cp70 and MCF-7 transfectants appeared
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and were large enough to be picked into the 24-well plates. At least 50% of the 
A2780cp70 transfectants were viable and were expanded into tissue culture flasks 
and frozen stocks were made. Tetracycline did not appear to play a role in the 
viability of the resistant A2780cp70 colonies, nor the MCF-7 transfectants. 
Colonies of G418-resistant MCF-7 transfectants appeared on the master plates in 
the presence and absence of tetracycline. These were picked into 24-well plates in 
the presence and absence of tetracycline and incubated as normal. 100% of these 
selected colonies proved to be inviable.
3.9.3 Preparation of GSE 7.10 For Use In The Tetracycline
Inducible Expression System
In order to induce expression of GSE7.10 in this system, it was necessary to sub­
clone the GSE into pUHD10-3, downstream of the heptamerised tet operator 
sequences. GSE 7.10 was cloned into the pLNCX vector as a HaeII / Clal 
fragment, however, this could not be easily cloned into the pUHD10-3 vector. 
Consequently, an intermediate vector had to be used in the sub-cloning process 
(see fig 3.9.1), pIC19R (97). The GSE was cut out of the pLNCX vector as a 
Hindlll / Clal fragment and the pIC19R vector was also digested with Hindlll / 
Clal. These digestions resulted in complementary ‘sticky ends’ allowing the GSE 
to ligate in a known orientation. In order to increase the percentage of specific 
ligations and reduce the number of religations and doublet formation, the reaction 
was also performed using dephosphorylated pIC19R. The pIC19R and GSE7.10 
Hindlll / Clal fragments were ligated as detailed in section 2.8.3, employing X- 
gal and ampicillin as selection procedures. The use of selection by a- 
complementation relies on the expression of p-lactamase from the lacZ gene on 
the pIC19R plasmid. When this gene is expressed, blue colonies form in the 
presence of X-gal and the inducer IPTG. The lacZ gene spans the multi-cloning 
site of pIC19R, therefore, if the GSE fragment were to successfully ligate into the 
vector, the lacZ gene would be disrupted and white colonies would result.
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Problems can arise if the insert DNA is a small enough fragment that does not 
prevent the lacZ gene from being expressed, in this case, blue colonies which 
would usually be ignored may contain the plasmid and ligated insert.
The ligation reactions were used to transform bacteria, and plasmid DNA from in 
excess of thirty white colonies was purified. Subsequent restriction digests of 
these DNA samples to confirm identity and the presence of accurate ligation 
products all resulted in DNA fragments whose size suggested that pIC19R 
doublets had formed. Plasmid DNA was then extracted from three blue colonies 
and digested in the same manner as the DNA extracted from the white colonies. 
All three samples revealed DNA fragments of a size consistent with successful 
ligation of GSE 7.10 into pIC19R by both Hindlll / Clal and BglI digestions 
(fig.3.9.2) It must therefore be assumed that the GSE is of such a size that read- 
through is possible.
3.10 p53 GSE's
The results described so far detail the analysis of cisplatin GSE’s which were 
generated by digestion of total HeLa cell cDNA. As previously mentioned 
however (section 1.6.2) it is possible to isolate GSE’s derived from digestion of a 
single gene cDNA. As there is a large body of evidence to suggest that p53 plays 
a pivotal role in the response to DNA damaging agents, including cisplatin, Liam 
Gallagher (CRC Dept, of Medical Oncology, University of Glasgow) has 
attempted to isolate genetic suppressor elements derived from both the human and 
murine p53 genes which confer resistance to cisplatin.
3.10.1 PCR Amplification of Cisplatin Selected GSE’s
A2780 cells which had previously been infected with vector containing both 
murine and human p53 GSE's were selected for resistance to cisplatin. The GSE's
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present in 32 of the resistant cell lines were isolated by PCR amplification and 
purified using the Wizard PCR Clean-Up protocol. Master mix was prepared as 
detailed (section 2.4.1), using lpg of primers P1785 and P1786, complimentary to 
pLNCX flanking DNA sequences, (see fig.3.4.1 for more detail). Figure 3.10.1 
shows the electrophoretic separation of these amplified sequences. It is clear from 
this data that increasing the stringency of cisplatin selection results in the isolation 
of cell populations which contain a single GSE i.e. in the less stringently selected 
samples, there are a number of products, whereas increased cisplatin 
concentrations result in a reduction in the number of products isolated. Four of 
the cell populations which appeared to have a strong band and little smearing 
(indicating a single amplified product) were sequenced and analysed in 
comparison with human p53 (Accession no. K03199). The results of this analysis 
are shown in the appendix and summarised in table 3.10.1.
It is clear from this and other data in the group that the GSE technique has great 
potential in terms of isolating p53 fragments which confer cisplatin resistance. If 
the system was of low selectivity, then the appearance of significant numbers of 
GSE's derived from the digested vector would be expected. This has not occurred.
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Figure 3.10.1 2% agarose gel separation of purified p53 GSE PCR
products
MW 10Obp ladder
mp53 GSE derived from murine p53
hp53 GSE derived from human p53
PAx designated name
xuM micromolar concentration of cisplatin selection carried
out over 24 hours
Table 3.10.1
Pages 84-87 describe the homology determined by sequence 
alignment for the p53 GSE’s described. Full details of the 
alignments are shown in the appendix.
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Chapter 4 Discussion
Although DNA damage is generally accepted as the chemotherapeutic target for 
cisplatin, the precise mechanisms by which cisplatin exerts its cytotoxic effects 
are not well characterised. As a result, it is difficult to ascertain all of the molecular
mechanisms which can confer resistance to cisplatin although some have been 
identifiedj (103). Many of the mechanisms so far identified are predicted to act in 
a dominant manner, that is, increased protein levels or activity results in increased 
drug resistance. The use of genetic suppressor elements offers a method with the 
potential to identify recessive mechanisms of drug resistance and may therefore 
elucidate novel mechanisms of resistance and help understand the exact 
mechanism of action of various drugs. Described in this study are two groups of 
GSE’s, those generated by DNasel digestion of an equalised total HeLa cDNA 
library i.e. the isolation of the cisplatin resistance GSE’s and those generated by 
DNasel digestion of a specific gene i.e. p53. Both groups have been isolated by 
cisplatin selection following introduction and retroviral expression in human cell 
lines.
The work presented here confirms the identity of a genetic suppressor element, 
designated GSE 7.10, as a 188bp fragment of the B-type isozyme of human 
phosphoglycerate mutase, an enzyme which is involved in the glycolytic pathway. 
This GSE was originally isolated as a consequence of selection for cisplatin 
resistance in HeLa cells and HT1080 cells after infection with the pLNCX~GSE 
7.10 construct (94). GSE 7.10 has been shown, in this study, to confer resistance
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to cisplatin in an additional cell line, the ovarian adenocarcinoma derived cell line, 
A2780. In addition, the response of the GSE 7.10 transfected A2780 lines to 
ionising radiation, another agent capable of causing DNA damage, has been 
investigated. The results of this aspect of the study suggest that GSE 7.10 can 
confer resistance to ionising radiation in the A2780 cell line. Assays designed to 
analyse the cell cycle characteristics of the GSE 7.10 transfectants in response to 
ionising radiation and cisplatin have also been carried out. They revealed the 
absence of a Gl/S phase checkpoint in cells transfected with GSE 7.10 in response 
to ionising radiation in one line of transfectants (A2.22), whereas another line 
transfected with the same GSE (A2.14) displayed a more modest reduction in 
arrest capability. The response of the GSE 7.10 transfectants to cisplatin mirrored 
those of the response to ionising radiation, in that the A2.22 line showed a 
significant reduction in the ability to arrest at the Gl/S checkpoint, whereas the 
A2.14 line appeared to have a fully functional arrest. The G2/M arrest was also 
examined in these assays. This arrest appears to be intact in response to ionising 
radiation, but the response to cisplatin treatment is less clear, as arrest appears to 
have been lost at the 6 hour time-point, but functional at 24 hours. These results 
require further confirmation.
Cisplatin and ionising radiation both result in DNA damage and this is thought to 
be the mechanism by which they exert their cytotoxic effects. One of the current 
models (see section 1.3.4) for the pathway which is initiated by DNA damage 
involves the elevation of p53 protein levels, in turn transactivating the WAF-1 
gene, leading to cell cycle arrest. As the presence of GSE 7.10 results in a loss (or 
at least a reduction) of Gl/S arrest capability, waf-1 RNA analysis is an important
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experiment in attempting to identify a possible pathway by which GSE 7.10 may 
function. The waf-1 RNA levels seen in the preliminary Northern experiment 
presented do not confirm or rule out the involvement of the p53 pathway in the 
activity of the GSE, as a control cell line known to have reduced levels of waf-1 
RNA, A2780cp70, showed no significant difference from the waf-1+ line, A2780, 
from which it was derived. This type of analysis would also be interesting to 
carry out on RNA isolated from the GSE transfectants following treatment with 
cisplatin, when waf-1 would be transcriptionally induced if the p53 pathway were 
intact.
There is much evidence from Gudkov's work that the GSE approach is a powerful 
way of identifying recessive mechanisms of drug resistance as well as identifying 
important functional areas of proteins. It is anticipated that the isolation of 
cisplatin GSE's derived from the p53 gene will not only be of use in manipulating 
the response to cisplatin but also provide further insight into the functional 
domains of the p53 protein. The early data suggests that this approach works well 
as the great majority of active GSE's are derived from the p53 gene and not from 
randomly digested sections of the pLNCX vector. The four p53 GSE's sequenced 
here show various levels of homology with the human p53 protein, and further 
sub-cloning and selection of these GSE's should result in a clearer gel band i.e. 
indicating the presence of a single GSE and more accurate sequencing data.
To unequivocally confirm many of the results presented here, the use of an 
inducible expression system will be important. Many of the older inducible 
systems lack the tight on/off control of the tetracycline system which has been 
developed by Bujard and Gossen (95), hence the reason for favouring this system.
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The work described here therefore confirms that GSE 7.10 confers resistance to 
cisplatin and ionising radiation and can result in the abrogation of cell cycle 
arrests induced by these agents. It does not however indicate the mechanism by 
which the GSE exerts these functions. The GSE acts in a sense orientation i.e. at 
the protein level, and is derived from the phosphoglycerate mutase-B gene. If the 
GSE were to be inhibiting the parental gene product i.e. the glycolytic enzyme, 
how could this produce changes in the response to DNA damage? It is widely 
acknowledged that diet can play an important role in the development of 
malignant disease. The role of glycolysis is to generate energy in the form of 
ATP by the conversion of glucose to pyruvate, as well as generating substrates for 
other biochemical processes. An important product of the respiratory pathway is 
NADH. A recent paper(104) describes a link between NAD and p53 expression. 
NAD is the main substrate of the enzyme PARP (polyADP ribose polymerase), 
and Whitacre et al. have demonstrated that a reduction in the available NAD pool 
or a reduction in PARP activity correlate with a reduction in p53 expression in 
response to DNA damage. Both p53 and PARP activities are known to increase in 
response to DNA damage, with the latter being induced within minutes of the 
damage occurring. This group have therefore hypothesised that PARP activity is 
in some way instrumental in the induction of p53 expression. If GSE 7.10 were 
blocking the activity of phosphoglycerate mutase-B, then the glycolytic pathway 
would be slowed so the availability of NAD may become a limiting factor in the 
induction of the p53 response. Examination of levels of NAD and polyADP 
ribose in the GSE transfectants would indicate whether it is altering the respiratory 
pathway.
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As the GSE is acting at the protein level, it is possible that its inhibitory activity is 
promiscuous in that it can compromise the activity of another enzyme or protein. 
If the protein fragment were to fold in such a way that it mimicked the 
phosphorylation site of another protein, then it could compete for the action of the 
relevant kinase. Alternatively, if its conformation is such that it is able to bind the 
active site of an enzyme then it could alter activity in this way. There are, 
therefore a large number of possible mechanisms of action of the GSE which 
remain to be defined.
The use of the tetracycline inducible system will be important in confirming the 
results presented here particularly for the cell cycle assays. This system will also 
facilitate additional characterisation to be carried out on the GSE 7.10 
transfectants. This GSE appears to confer the ability for cells to continue through 
the normal Gl/S checkpoint following treatment with DNA damaging agents 
which normally induce this arrest. Apoptosis is an additional (or subsequent) 
event which has been shown to occur in response to DNA damage. FACS 
analysis of the GSE transfectants in response to cisplatin and ionising radiation 
treatment is a crucial experiment to carry out in order to examine the extent of the 
activity of the GSE in response to DNA damage. If the GSE is also capable of 
blocking the apoptotic response to DNA damage, it would be implicated in both of 
the central response pathways to DNA damage. The resistance, cell cycle and 
apoptosis assays would also be interesting to perform with cytotoxic agents which 
do not act via a DNA damage pathway e.g. taxol.
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As the GSE is acting in a sense orientation i.e. at the protein level, it will be 
interesting to determine the proteins with which the GSE peptide interacts. There 
are a number of methods which could be used to identify such proteins, for 
example, immunoprecipitation assays potentially using the GSE as a GST fusion 
protein, the yeast two hybrid system and ELISA. Analysis of the primary 
sequence of the GSE may offer an insight into possible interactions as could a 
model of the putative secondary structure, prior to the interaction assays. 
Sequence motifs could reveal consensus sequences of potential binding sites for 
proteins involved in key cell cycle events or other biochemical processes. If the 
GSE were blocking the activity of the parental gene product, i.e. phosphoglycerate 
mutase-B, then overexpression of the parental gene may expose an increased 
sensitivity to cytotoxic agents.
The GSE method has been shown to be a powerful technique for identifying genes 
and regions of proteins important in a drug resistant phenotype. The identification 
of a fragment of the human phosphoglycerate mutase-B gene as a cisplatin GSE 
which also results in cell cycle peturbations in response to DNA damage 
potentially exposes a novel mechanism (or a new molecule) involved in the 
resistance to DNA damaging agents.
94
References
1. Loehrer, P.J. and Einhom, L.H. Diagnosis and treatment: drugs five years later. 
Ann. Intern. Med., 100: 704-713, 1984.
2. Rosenberg, B., Vancamp, L., and Krigas, T. Inhibition of cell division in 
Escherichia coli by electrolysis products from a platinum electrode. Nature, 205: 
698-699, 1965.
3. Rosenberg, B. and Vancamp, L. The successful regression of large solid 
sarcoma 180 tumours by platinum compounds. Cancer Res., 30: 1799-1802,
1970.
4. Fichtinger-Shepman, A.M.J., van der Veer, J.L., den Hartog, J.H.J., Lohman, 
P.H.M., and Reedijk, J. Adducts of the antitumour drug cis- 
diamminedichloroplatinum(II) with DNA : formation, identification and 
quantitation. Biochemistry, 24: 707-713, 1985.
5. Pinto, A.L. and Lippard, S.J. Binding of the anti-tumour drug czs-platinum(II) 
(cisplatin) to DNA. Biochimica. Et. Biophysica. Acta, 780: 167-180, 1985.
6. Eastman, A. Re-evaluation of interaction of ds-dichloro (ethylenediammine) 
platinum(II) with DNA. Biochemistry, 25(13): 3912-3915, 1986.
7. Szymkowski, D.E., Yarema, K., Essigmann, J.M., Lippard, S.J., and Wood, 
R.D. An intrastrand d(GpG) platinum crosslink in duplex M l3 DNA is refractory
96
to repair by human cell extracts. Proc. Natl. Acad. Sci. USA, 89: 10772-10776, 
1992.
8. Bruhn, S.L., Pil, P.M., Essigmann, J.M., Housman, D.E., and Lippard, S.J. 
Isolation and characterization of human cDNA clones encoding a high mobility 
group box protein that recognizes structural distortions to DNA caused by binding 
of the anticancer agent cisplatin. Proc. Natl. Acad. Sci. USA, 89: 2307-2311, 
1992.
9. Ciccarelli, R.B., Solomon, M.J., Varshavsky, A., and Lippard, SJ. In vivo 
effects of cis- and /nms'-diamminedichloroplatinum(II) on SV40 chromosomes: 
differential repair, DNA-protein cross-linking, and inhibition of replication. 
Biochemistry, 24: 7533-7540, 1985.
10. Lane, D.P. p53, guardian of the genome. Nature, 358: 15-16, 1992.
11. Rao, P.N. and Johnson, R.T. Mammalian cell fusion : studies on the regulation 
of DNA synthesis and mitosis. Nature, 225: 159-164, 1970.
12. Johnson, R.T. and Rao, P.N. Mammalian cell fusion : induction of premature 
chromosome condensation in interphase nuclei. Nature, 226: 717-722, 1970.
97
13. Forsburg, S. and Nurse, P. Cell cycle regulation in the yeasts Saccharomyces 
cerevisiae and Schizosaccharomyces pombe. Annual Review Cell Biology, 7: 
227-256, 1991.
14. Nasmyth, K. Control of the yeast cell cycle by the Cdc28 protein kinase. 
Current Opinion in Cell Biology, 5: 166-179, 1993.
15. Sherr, C.J. Mammalian G1 Cyclins. Cell, 73: 1059-1065, 1993.
16. Masui, Y. and Markert, C. Cytoplasmic control of nuclear behaviour during 
meiotic maturation of frog oocytes. Journal of Experimental Zoology, 177: 129,
1971.
17. Lohka, M.J., Hayes, M.K., and Mailer, J.L. Purification of MPF, an 
intracellular regulator of early mitotic events. Proc. Natl. Acad. Sci. USA, 85: 
3009-3013, 1988.
18. Evans, T., Rosenthal, E.T., Youngblom, J., Distel, D., and Hunt, T. Cyclin: a 
protein specified by maternal mRNA in sea urchin eggs that is destroyed at each 
cleavage division. Cell, 33: 389-396, 1983.
19. Morgan, D.O. Principles of CDK regulation. Nature, 374: 131-134, 1995.
98
20. Weinert, T.A. and Hartwell, L.H. The RAD9 gene controls the cell cycle 
response to DNA damage in Saccharomyces cerevisiae. Science, 241: 317-322, 
1988.
21. Sorenson, C.M. and Eastman, A. Mechanisms of cis- 
diamminedichloroplatinum(II)-induced cytotoxicity : role of G2 arrest and DNA 
double-strand breaks. Cancer Research, 48: 4484-4488, 1988.
22. Weinert, T.A., Kiser, G.L., and Hartwell, L.H. Mitotic checkpoint genes in 
budding yeast and the dependence of mitosis on DNA replication and repair. 
Genes Dev., 8: 652-665, 1994.
23. Zakian, V.A. ATM-related genes : What do they tell us about functions of the 
human gene?. Cell, 82: 685-687, 1995.
24. Greenwell, P.W., Kronmal, S.L., Porter, S.E., Gassenhuber, J., Obermaier, B., 
and Petes, T.D. TEL1, a gene involved in controlling telomere length in 
S.cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell, 82: 
823-829, 1995.
25. Morrow, D.M., Tagle, D.A., Shiloh, Y., Collins, F.S., and Hieter, P. TEL1, an 
S. cerevisiae homologue of the human gene mutated in ataxia telangiectasia, is 
functionally related to the yeast checkpoint gene MEC1. Cell, 82: 831-840, 1995.
99
26. Paulovich, A.G. and Hartwell, L.H. A checkpoint regulates the rate of 
progression through S phase in S. cerevisiae in response to DNA damage. Cell, 
82: 841-847, 1995.
27. Hartley, K.O., Gell, D., Smith, G.C.M., Zhang, H., Divecha, N., Connelly, 
M.A., Admon, A., Lees-Miller, S.P., Anderson, C.W., and Jackson, S.P. DNA- 
dependent protein kinase catalytic subunit: a relative of phosphatidylinositiol 3- 
kinase and the ataxia telangiectasia gene product. Cell, 82: 849-856, 1995.
28. Dunphy, W.G. The decision to enter mitosis. Trends in Cell Biology., 4: 202- 
207, 1994.
29. El-Deiry, W.S., Harper, J.W., O'Connor, P.M., Velculescu, V.E., Canman, 
C.E., Jackman, J., Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y., Wiman, 
K.G., Mercer, W.E., Kastan, M.B., Kohn, K.W., Elledge, S.J., Kinzler, K.W., and 
Vogelstein, B. WAF-l/CIP-1 is induced in p53-mediated G1 arrest and apoptosis. 
Cancer Research., 54: 1169-1174, 1994.
30. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, 
J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. WAF-1, a 
potential mediator of p53 tumour suppression. Cell, 75: 817-825, 1993.
31. Flores-rozas, H., Kelman, Z., Dean, F.B., Pan, Z., Harper, J.W., Elledge, S.J., 
O'Donnell, M., and Hurwitz, J. Cdk-interacting protein-1 (Cipl, WAF1) directly
100
binds with proliferating cell nuclear antigen and inhibits DNA replication 
catalyzed by the DNA polymerase 5 holoenzyme. Proc. Natl. Acad. Sci. USA, 91: 
8655-8659, 1994.
32. Nelson, W.G. and Kastan, M.B. DNA strand breaks: The DNA template 
alterations that trigger p53-dependent-DNA damage response pathways. Mol. 
Cell. Biol., 14: 1815-1823,1994.
33. Chu, G. and Chang, E. Cisplatin-resistant cells express increased levels of a 
factor that recognises damaged DNA. Proc. Natl. Acad. Sci. USA, 87: 3324-3327, 
1990.
34. McLaughlin, K., Coren, G., Masters, J., and Brown, R. Binding activities of 
cis-platin-damage-recognition proteins in human tumour cell lines. International 
Journal of Cancer, 53: 662-666, 1993.
35. Donahue, B.A., Augot, M., Bellon, S.F., Treiber, D.K., Toney, J.H., Lippard,
S.J., and Essigmann, J.M. Characterisation of a DNA damage recognition protein 
from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) 
DNA adducts of the anticancer drug cisplatin. Biochemistry, 29: 5872-5880, 
1990.
101
36. Hughes, E.N., Engelsberg, B.N., and Billings, P.C. Purification of nuclear 
proteins that bind to cisplatin- damaged DNA Identity with high mobility group 
proteins 1 and 2. Journal of Biological Chemistry, 267: 13520-13527, 1992.
37. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. p53 mutations in 
human cancers. Science, 253: 49-53, 1991.
38. Harris, C.C. p53: At the crossroads of molecular carcinogenesis and risk 
assessment. Science, 262: 1980-1981, 1993.
39. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. p53 and its 14kDa C-terminal 
domain recognize primary DNA damage in the form of insertion/deletion 
mismatches. Cell, 81: 1013-1020, 1995.
40. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, 
C.A., Butel, J.S., and Bradley, A. Mice deficient for p53 are developmentally 
normal but susceptible to spontaneous tumours. Nature, 356: 215-221, 1992.
41. Mercer, W.E., Amin, M., Sauve, G.J., Appella, E., Ullrich, S.J., and Romano, 
J.W. Wild-type human p53 is antiproliferative in SV40-transformed hamster cells. 
Oncogene, 5: 973-980, 1990.
102
42. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of 
transformation and of cell proliferation by a temperature sensitive mutant of p53. 
Cell, 62: 671-680, 1990.
43. Shaulian, E., Zauberman, A., Ginsberg, D., and Oren, M. Identification of a 
minimal transforming domain of p53: negative dominance through abrogation of 
sequence-specific DNA binding. Molecular and Cellular Biology, 12 (12): 5581- 
5592, 1992.
44. Mcllwrath, A.J., Vasey, P.A., Ross, G.M., and Brown, R. Cell cycle arrests 
and radiosensitivity of human tumour cell lines: Dependence on wild-type p53 for 
radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
45. Hall, P.A., McKee, P.H., Menage, H.D., Dover, R., and Lane, D.P. High levels 
of p53 protein in UV-irradiated normal human skin. Oncogene, 8: 203-207, 1993.
46. Midgley, C.A., Owens, B., Briscoe, C.V., Thomas, D.B., Lane, D.P., and Hall, 
P.A. Coupling between gamma irradiation, p53 induction and the apoptotic 
response depends on cell type in vivo. J. Cell Sci., 108: 1843-1848, 1995.
47. Stewart, N., Hicks, G.G., Paraskevas, F., and Mowat, M. Evidence for a 
second cell cycle block at G2/M by p53. Oncogene, 10: 109-115, 1995.
103
48. Hickman, E.S., Picksley, S.M., and Vousden, K.H. Cells expressing HPV16 
E7 continue cell cycle progression following DNA damage induced p53 
activation. Oncogene, 9(8): 2177-2181, 1994.
49. Kadohama, T., Tsuji, K., and Ogawa, K. Indistinct cell cycle checkpoint after
u.v. damage in H-ras-transformed mouse liver cells despite normal p53 gene 
expression. Oncogene, 9(10): 2845-2852, 1994.
50. Okamoto, K. and Beach, D. Cyclin G is a transcriptional target of the p53 
tumour suppressor protein. EMBO J., 13(20): 4816-4822, 1994.
51. Zhan, Q., Bae, I., Kastan, M.B., and Fomace Jr, A.J. The p53-dependent 
gamma-ray response of GADD45. Cancer Res., 54(10): 2755-2760, 1994.
52. Barak, Y., Juven, T., Haffner, R., and Oren, M. Mdm2 expression is induced 
by wild-type p53 activity. EMBO J., 12(2): 461-468, 1993.
53. Xiong, Y., Zhang, H., and Beach, D. D-type cyclins associate with multiple 
protein kinases and the DNA replication and repair factor PCNA. Cell, 71: 504- 
514, 1992.
54. Li, R., Waga, S., Hannon, G.J., Beach, D., and Stillman, B. Differential effects 
by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. 
Nature, 371: 534-537, 1994.
104
55. Kerr, J.F.R., Wyllie, A.H., and Currie, A.R. Apoptosis: A basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 26: 
239-257, 1972.
56. Wyllie, A.H. Apoptosis (The Frank Rose Memorial Lecture). Br. J. Cancer, 
67: 205-208, 1993.
57. Ormerod, M.G., O'Neill, C.F., Robertson, D., and Harrap, K.R. Cisplatin 
induces apoptosis in a human ovarian carcinoma cell line without concomitant 
intemucleosomal degradation of DNA. Exp. Cell Res., 211(2): 231-237,1994.
58. Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, 
M., Waters, C.M., Penn, L.Z., and Hancock, D.C. Induction of apoptosis in 
fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
59. Lowe, S.W., Scmitt, E.M., Osborne, B.A., and Jacks, T. p53 is required for 
radiation-induced apoptosis in mouse thymocytes. Nature, 362: 847-849, 1993.
60. Zhu, Y.M., Bradbury, D.A., and Russell, N.H. Wild-type p53 is required for 
apoptosis induced by growth factor deprivation in factor-dependent leukaemic 
cells. Br. J. Cancer, 69(3): 468-472, 1994.
61. Dive, C. and Hickman, J.A. Drug-target interactions: only the first step in the 
commitment to a programmed cell death?. Br. J. Cancer, 64: 192-196, 1991.
105
62. Frankfurt, O.S., Seckinger, D., and Sugarbaker, E.V. Apoptosis and growth 
inhibition in sensitive and resistant leukaemic cells treated with anticancer drugs.. 
Int. J. Oncol., 4: 481-489, 1994.
63. Song, Q.Z., Baxter, G.D., Kovacs, E.M., Findik, D., and Lavin, M.F. 
Inhibition of apoptosis in human tumour cells by okadaic acid. J. Cell. Physiol., 
153(3): 550-556, 1992.
64. Evans, D.L., Tilby, M., and Dive, C. Differential sensitivity to the induction of 
apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is 
independent of the level of drug accumulation and DNA adduct formation. 
Cancer Res., 54: 1596-1603, 1994.
65. Walker, M.C., Parris, C.N., and Masters, J.R.W. Differential sensitivities of 
human testicular and bladder tumor cell lines to chemotherapeutic drugs.. J. Natl. 
Cancer Inst., 79: 213-216, 1987.
66. Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, 
J., Lonie, K.G., Knutsen, T., McKoy, W.M., Young, R.C., and Ozols, R.F. 
Characterisation of a czs-diamminedichlojoplatinum II resistant human ovarian 
cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47: 
414-418, 1987.
106
67. McLaughlin, K., Stephens, I., McMahon, N., and Brown, R. Single step 
selection of c/s-diamminedichloroplatinum(II) resistant mutants from a human 
ovarian carcinoma cell line. Cancer Res., 51: 2242-2245, 1991.
68. Kessel, D., Botteril, V., and Wodinsky, I. Uptake and retention of daunomycin 
by mouse leukaemia cells as factors in drug response. Cancer Res., 28: 938-941, 
1968.
69. Biedler, J.L. and Riehm, H. Cellular resistance to actinomycin D in Chinese 
hamster cells in vitro : cross-resistance, radioautographic and cytogenetic studies. 
Cancer Res., 30: 1174-1184, 1970.
70. Ling, V. and Thompson, L.H. Reduced permeability in CHO cells as a 
mechanism of resistance to colchicine. J. Cell. Physiol., 83: 103-116, 1974.
71. Juliano, R.L. and Ling, V. A surface glycoprotein modulating drug 
permeability in CHO mutants. Biochimica. Et. Biophysica. Acta, 455: 152-162, 
1976.
72. j Van der Bliek, A.M., Van der Velde-Koerts, T., Ling, V., et al. 
Overexpression and amplification of five genes in a multi-drug resistant Chinese 
hamster ovary cell line. Mol. Cell Biol., 6: 1671-1678, 1986.
107
73. Gros, P., Croop, J., and Housman, D.E. Mammalian multi-drug resistance 
gene : complete cDNA sequence indicates strong homology to bacterial transport 
proteins. Cell, 47: 371-380, 1986.
74. Bradley, G., Juranka, P.F., and Ling, V. Mechanisms of multi-drug resistance. 
Biochimica. Et. Biophysica. Acta, 948: 87-128, 1988.
75. Deuchars, K.L. and Ling, V. P-glycoprotein and multidrug resistance in cancer 
chemotherapy. Semin-Oncol., 16 (2): 156-165, 1989.
76. Melvik, J.E., Domish, J.M., and Pettersen, E.O. The binding of cis- 
dichlorodiamminplatinum(II) to extracellular and intracellular compounds in 
relation to drug uptake and cytotoxicity in vitro. Brit J. Cancer, 66: 260-265, 
1992.
77. Andrews, P.A., Murphy, M.P., and Howell, S.B. Characterization of cisplatin- 
resistant COLO 316 human ovarian carcinoma cells. European. Journal, of. 
Cancer &. Clinical. Oncology, 1989.
78. Schmidt, W. and Chaney, S.G. Role of carrier ligand in platinum resistance of 
human carcinoma cell lines. Cancer Res., 53: 799-805, 1993.
108
79. Famworth, P., Hillcoat, B., and Roos, I. Metallothionein-like proteins and cell 
resistance to ds-dichlorodiammineplatinum(II) in L1210 cells. Cancer 
Chemotherapy &. Pharmacology, 25: 411-417, 1990.
80. Hansson, J. and Wood, R.D. Repair synthesis by human cell extracts in DNA 
damaged by cis-and frafts-diamminedichloroplatinum(II). Nucleic Acids Res., 17: 
8073-8091, 1989.
81. Sorenson, C.M. and Eastman, A. Influence of cis- 
diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in 
excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res., 
48 (23): 6703-6707, 1988.
82. Lai, G.M., Ozols, R.F., Smyth, J.F., Young, R.C., and Hamilton, T.C. 
Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. 
Biochem. Pharmacol., 37: 4597-4600, 1988.
83. Bedford, P., Fichtinger-Schepman, A.M.J., Shellard, S.A., Walker, M.C., 
Masters, J.R.W., and Hill, B.T. Differential repair of platinum-DNA adducts in 
human bladder and testicular tumor continuous cell lines. Cancer Res., 48: 3019- 
3024, 1988.
84. Dalton, W.S. Is p-glycoprotein a potential target for reversing clinical drug 
resistance?. Current. Opin. Oncol., 6 (6): 595-600, 1994.
109
85. Dole, M., Nunez, G., Merchent, A.K., Rode, C.K., Bloch, C.A., and Castle, 
V.P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer 
Res., 54 (12): 3253-3259, 1994.
86. Hockenbery, D.M. Bcl-2, a novel regulator of cell death. BioEssays, 17 (7): 
631-638, 1995.
87. Kondo, S., Barnett, G.H., Hara, H., Morimura, T., and Takeuchi, J. MDM2 
protein confers the resistance of a human glioblastoma cell line to cisplatin- 
induced apoptosis. Oncogene, 10: 2001-2006,1995.
88. Scanlon, K.J., Kashani-Sabet, M., and Sowers, L.C. Overexpression of DNA 
replication and repair enzymes in cisplatin-resistant human colon carcinoma 
HCT8 cells and circumvention by azidothymidine. Cancer Communications., 1: 
269-275, 1989.
89. Lu, S.J., Man, S., Bani, M.R., Adachi, D., Hawley, R.G., Kerbel, R.S., and 
Ben-David, Y. Retroviral insertional mutagenesis as a strategy for the 
identification of genes associated with ds-diamminedichloroplatinum(II) 
resistance. Cancer Res., 55 (5): 1139-1145, 1995.
90. Roninson, I.B., Gudkov, A.V., Holzmayer, T.A., Kirschling, D.J., Kazarov, 
A.R., Zelnick, C.L., Mazo, I.A., Axenovich, S., and Thimmapaya, R. Genetic
110
suppressor elements : new tools for molecular oncology - Thirteenth Cornelius P. 
Rhoads Memorial Award Lecture. Cancer Res., 55: 4023-4028, 1995.
91. Gudkov, A.V., Zelnick, C.R., Kazarov, A.R., Thimmapaya, R., Suttle, D.P., 
Beck, W.T., and Roninson, I.B. Isolation of genetic suppressor elements, inducing 
resistance to topoisomerase II-interactive cytotoxic drugs, from human 
topoisomerase II cDNA. Proc. Natl. Acad. Sci. USA, 90: 3231-3235, 1993.
92. Brooks, S.C., Locke, E.R., and Soule, H.D. Estrogen receptor in a human cell 
line (MCF-7) from breast carcinoma. Journal of Biological Chemistry, 248 (17): 
6251-6253, 1973.
93. Gudkov, A.V., Kazarov, A.R., Thimmapaya, R., Axenovich, S.A., Mazo, I.A., 
and Roninson, I.B. Cloning mammalian genes by expression selection of genetic 
suppressor elements: Association of kinesin with drug resistance and cell 
immortalization. Proc. Natl. Acad. Sci. USA, 91: 3744-3748, 1994.
94. Kirschling, D.J., Gudkov, A.V., and Roninson, I.B. Identification of genes 
responsible for cisplatin sensitivity in human cells. Proc. Amer. Assoc. Cancer 
Res., 35: 4381994. (Abstract)
95. Gossen, M. and Bujard, H. Tight control of gene expression in mammalian 
cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89: 5547- 
5551, 1992.
Il l
96. Miller, A.D. and Rosman, G.J. Improved retroviral vectors for gene transfer 
and expression. BioTechniques, 7: 980-990, 1989.
97. Marsh, J.L., Erfle, M., and Wykes, E.J. The pIC plasmid and phage vectors 
with versatile cloning sites for recombinant selection by insertional inactivation. 
Gene, 32: 481-485, 1984.
98. Southern, P.J. and Berg, P. Transformation of mammalian cells to antibiotic 
resistance with a bacterial gene under control of the SV40 early region promoter. 
J. Mol. Appl. Genet., 1 (4): 1982.
99. Sambrook, J., Fritsch, E.F., and Maniatis, T. Molecular cloning : a laboratory 
manual. NY: Cold Spring Harbor Laboratory Press, 1989.
100. Sanger, F., Nicklen, S., and Coulson, A.R. DNA sequencing with chain- 
terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
101. Sakoda, S., Shanske, S., DiMauro, S., and Schon, E.A. Isolation of a cDNA 
encoding the B isozyme of human phosphoglycerate mutase (PGAM) and 
characterisation of the PGAM gene family. J. Biol. Chem., 263 (32): 16899- 
16905, 1988.
112
102. Brown, R., Clugston, C., Bums, P., Edlin, A., Vasey, P., Vojtesek, B., and 
Kaye, S.B. Increased accumulation of p53 in cisplatin-resistant ovarian cell lines. 
Int. J. Cancer, 55: 678-684, 1993.
103. Andrews, P.A. and Howell, S.B. Cellular pharmacology of cisplatin: 
perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990.
104. Whitacre, C.M., Hashimoto, H., Tsai, M., Chatterjee, S., Berger, S.J., and 
Berger, N.A. Involvement of NAD-Poly(ADP-ribose) metabolism in p53 
regulation and its consequences. Cancer Res., 55: 3697-3701, 1995.
105. Fry, A.M., Chresta, C.M., Davies, S.M., Walker, M.C., Harris, A.L., Hartley, 
J.A., Masters, J.R.W. and Hickson, I.D. Relationship between topoisomerase II 
level and chemosensitivity in human tumour cell lines. Cancer Res., 51: 6592- 
6595, 1991.
113
tA p p e n d i x  : Sequence u4&gnment oj 
pSS-cDe/iived CispJatin QS8's
Appendix: Sequence Alignment of p53-Derived Cisplatin GSE's
Sequence Alignment of Forward (primer h2693) and Reverse 
(primer H2694) Primed Strands of hp53 PA5 B1
a) 82.0% identity in 189 bp overlap
2 1 9  2 0 9  1 9 9  1 8 9  1 7 9  1 6 9
H 26 9 3 ATCCACGCTGTTTTGACCTCCATAGAAGACAACGGGACCGATCCAGCCTCCGCGGCCCCA
II II M I N I M  M i l l  1111111
H2 6 9 4  CCTTTGNGNTATACACGGCCCNGGCCCCCAAAAAGGTTCGATCCAGTCTCCGTGGCCCCA 
1 0  2 0  3 0  4 0  5 0  6 0
1 5 9  1 4 9  1 3 9  1 2 9  1 1 9  1 0 9
H 26 9 3 AGCTTATGGATGGATGAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGT
II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
H2 6 9 4  CGCTTATGGATGGATGAGCACCGGCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG 
7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
9 9  8 9  7 9  6 9  5 9  4 9
H 26 9 3 CTGCTGCCAGTGGCGATAAGTCGTGTCTGAGTGAGTGAATCGATCGGGGCCCAGATTTTA
I II I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
H 26 9 4  CTGCTGCCAGTGGCGATAAGTCGGGTCTGAGTGAGTGAATCGATAAAATAAAAGATTTTA 
1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0
3 9  2 9  1 9  9
H2 6 9 3 TTTAGTCTCCANATTTTGGGGCTGCTGAAAGCNNNNNNCNCA
I I I I I I I I I I I : I I I I I  l l l l l l  : : : : : : | :
H 26 9 4  TTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCTGTAGGTTTGGCAAGCTGCTA 
1 9 0  2 0 0  2 1 0  2 2 0  2 3 0  2 4 0
b) 100.0% identity in 8 bp overlap
1 0  2 0  3 0  4 0  5 0
H2 6 9 3 TGNGNNNNNNGCTTTCAGCAGCCCCAAAATNTGGAGACTAAATAAAATCTGGGCCC
I I I I II I I
H 26 9 4  CCTTTGNGNTATACACGGCCCNGGCCCCCAAAAAGGTTCGATCCAGTCTCCGTGGCCCCA 
1 0  2 0  3 0  4 0  5 0  6 0
Sequence Alignment of hp53 PA5 B1 (H2693) With Human p53t, 
Accession no. K03199
a) 72.7% identity in 22 bp overlap
7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
H 26 9 3 CGATTCACTCACTCAGACACGACTTATCGCCACTGGCAGCAGACACTGGTAACAGGATTA
M i n i  i i  i i  m i l l
h u m p 5 3  TGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGG 
9 6 0  9 7 0  9 8 0  9 9 0  1 0 0 0  1 0 1 0
B
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Appendix: Sequence Alignment of p53-Derived Cisplatin GSE's
b) 66.7% identity in 48 bp overlap
2 1 9  2 0 9  1 9 9  1 8 9  1 7 9  1 6 9
H2 6 9 3 GACGCCATCCACGCTGTTTTGACCTCCATAGAAGACAACGGGACCGATCCAGCCTCCGCG
I I I  M i l l  I I I I I  II  II
hu m p53  ACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAAC— GTTCTGTCC— CCCTTGCC 
2 7 0  2 8 0  2 9 0  3 0 0  3 1 0  3 2 0
1 5 9  1 4 9  1 3 9  1 2 9  1 1 9  1 0 9
H 26 9 3  GCCCCAAGCTTATGGATGGATGAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTAC
M I N I M  l l l l l l l
h u m p 53  GTCCCAAGC-AATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTG 
3 3 0  3 4 0  3 5 0  3 6 0  3 7 0  3 8 0
Sequence Alignment of hp53 PA5 B1 (H2694) With Human p53t, 
Accession no. K03199
a) 77.3% identity in 22 bp overlap
1 5 9  1 4 9  1 3 9  1 2 9  1 1 9  1 0 9
H2 6 9 4 CGATTCACTCACTCAGACCCGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTA
m i l l  i i  i i i  m i l l
h u m p5 3  TGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGG 
9 6 0  9 7 0  9 8 0  9 9 0  1 0 0 0  1 0 1 0
b) 60.0% identity in 45 bp overlap
1 9 0  2 0 0  2 1 0  2 2 0  2 3 0
H 26 9 4  TTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCACCTGTAGGTTTGGCAAGCTG— C
I II II  I I I N I  II I I I I  I
hu m p5 3  GCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCC 
5 7 0  5 8 0  5 9 0  6 0 0  6 1 0  6 2 0
2 4 0  2 5 0  2 5 9
H2 6 9 4  TAAACCCACCCNGGGANCTNG
i i n  h i m  i
h u m p 53  AAGACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGC 
6 3 0  6 4 0  6 5 0  6 6 0  6 7 0  6 8 0
c
Appendix: Sequence Alignment of p53-Derived Cisplatin GSE's
Sequence Alignment of Forward (primer h2693) and Reverse 
(primer H2694) Primed Strands of hp53 PA4 B1
a) 82.7% identity in 220 bp overlap
2 6 9  2 5 9  2 4 9  2 3 9  2 2 9  2 1 9
H 2 6 9 4  TGCCAAACCTACAGGTGGGGTCTTTCATTCCCCCCTTTTTCTGGAGACTAAATAAAATCT
H 2 9 6 3 AANAGGNCNGNNAATAANTNCCAGGGCCCCCAATATTTNGAGACTAAATAAATTCT
10 20 3 0 4 0 5 0
2 0 9 1 9 9
I I I
6 0 7 0
1 8 9 1 7 9
: I I II
8 0 9 0
1 6 9
100
1 5 9
H 26 9 4  TTTATTTTATCGATTCACTCANTCATGGNAGTCCTGGGTGCTTCTGACCCACACCTATTG
II
H2 9 6  3 GGCCNTTTATCGATTCACTCACTCATGGAAGTCCTGGGTGATTCTGACGCACACCTATTG
110
1 4 9 1 3 9
120 1 3 0
1 2 9 1 1 9
1 4 0 1 5 0
1 0 9
1 6 0
9 9
H2 9 6 4 CAANCAAGGGTTCAAAGACCCAAAATCCATAATGCCAGGGGAGGGAGAGATGGGGGTGGG
II l : l I I I I I II II II I I II I I I I I I I  I I I  l l l l l l l l l l l l l l l l  I I I II II
H2 96  3 CAAGCAAGGGTTCAAAGACCCAAGACCCAATATGGCAGGGGAGGGAGAGATTGGGGTGGC
1 7 0
8 9 7 9
II
1 8 0 1 9 0
6 9 5 9
II II
200 210
4 9
220
3 9
H2 9 6 4 AGACTGTCAGTGGGGAACAAGAAGCATCTATCCATGAGCGTGGGACCACGGAGGCTGAAT
II
H2 9 6 3 AGGCTGCCAGTGGGGAACAGTAAGTATCCATCCATAAGCTTGGGGCCGCGGAGGCTGGAT
2 3 0
2 9 1 9
H 2 9 6 4  CGAAANCGGTCGGGGGCCCTTAAGNCNNTT
: I I
H2 96  3 CGGTCCCGGTGTCTTCTATGGAGGTCAAAACAGCGTGGATGGCGTCTCAAGGG
2 4 0 2 5 0 2 6 0 2 7 0 2 8 0
b) 63.4% identity in 41 bp overlap
20 3 0 4 0 5 0 6 0
H 2 9 6 3
II
7 0
H2 9 6  4 CCCCGACCGNTTTCGATTCAGCCTCCGTGGTCCCACGCTCATGGATAGATGCTTCTTGTT
AGACTAAATAAATTCTGGCCNTTTATCGATTCACTCACTCATGGA-AG-TCCTGGGTGAT 
5 0  6 0  7 0  8 0  9 0
8 0  9 0  1 0 0  1 1 0  1 2 0  1 3 0
H 2 6 9 4  CCCCACTGACAGTCTCCCACCCCCATCTCTCCCTCCCCTGGCATTATGGATTTTGGGTCT
I II  I I I
H2 6 9 3 TCTGACGCACACCTATTGCAAGCAAGGGTTCAAAGACCCAAGACCCAATATGGCAGGGGA 
1 0 0  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
D
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Appendix: Sequence Alignment of p53-Derived Cisplatin GSE's
Sequence Alignment of hp53 PA4 B1 (H2693) With Human p53t,
Accession no. K03199
a) 93.4% identity in 121 bp overlap
2 2 9  2 1 9  2 0 9  1 9 9  1 8 9  1 7 9
H 26 9 3  GCCTCCGCGGCCCCAAGCTTATGGATGGATACTTACTGTTCCCCACTGGCAGCCTGCCAC
I N I  l l l l l l l l l l l l  M I N I  I N I
h u m p53 AGAAGGGCCTGACTCAGACTGACATTCTCCACTTCTTGTTCCCCACTGACAGCCTCCCAC 
1 3 8 0  1 3 9 0  1 4 0 0  1 4 1 0  1 4 2 0  1 4 3 0
1 6 9  1 5 9  1 4 9  1 3 9  1 2 9  1 1 9
H2 6 9 3 CCCAATCTCTCCCTCCCCTGCCATATTGGGTCTTGGGTCTTTGAACCCTTGCTTGCAATA
i i i  i i i i i i i i i i i i i i i i i i i i  l i n n  i i i i i i i i i i i i i i i i i i i i i i i i i i i i
h u m p 5 3 CCCCATCTCTCCCTCCCCTGCCATTTTGGGTTTTGGGTCTTTGAACCCTTGCTTGCAATA 
1 4 4 0  1 4 5 0  1 4 6 0  1 4 7 0  1 4 8 0  1 4 9 0
1 0 9  9 9  8 9  7 9  6 9  5 9
H 26 9 3 GGTGTGCGTCAGAATCACCCAGGACTTCCATGAGTGAGTGAATCGATAAANGGCCAGAAT
l l l l l l l l l l l l l l  I I I I I I I I I II I I I I I
hu m p53 GGTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGGGCTCCACTGAACAA 
1 5 0 0  1 5 1 0  1 5 2 0  1 5 3 0  1 5 4 0  1 5 5 0
b) 78.3% identity in 23 bp overlap
6 0  7 0  8 0  9 0  1 0 0  1 1 0
H2 6 9 3 GGCCNTTTATCGATTCACTCACTCATGGAAGTCCTGGGTGATTCTGACGCACACCTATTG
M I N I M  II I I M i l l !
hu m p53 GGAACAGCTTTGAGGTGCATGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAG 
1 0 2 0  1 0 3 0  1 0 4 0  1 0 5 0  1 0 6 0  1 0 7 0
Sequence Alignment of hp53 PA4 B1 (H2694) With Human p53t,
Accession no. K03199
a) 94.2% identity in 120 bp overlap
4 0
1 3 8 0
5 0
1 3 9 0
6 0 7 0 8 0
II
1 4 0 0 1 4 1 0 1 4 2 0
9 0
H2 6 9 4  CCTCCGTGGTCCCACGCTCATGGATAGATGCTTCTTGTTCCCCACTGACAGTCTCCCACC
M I N I M  I I I I
hu m p53 GAAGGGCCTGACTCAGACTGACATTCTCCACTTCTTGTTCCCCACTGACAGCCTCCCACC
1 4 3 0
100
II
1 4 4 0
110
II
1 4 5 0
120 1 3 0 1 4 0
II  I I I I  I I I
1 4 6 0 1 4 7 0 1 4 8 0
1 5 0
H2 6 9 4  CCCATCTCTCCCTCCCCTGGCATTATGGATTTTGGGTCTTTGAACCCTTGNTTGCAATAG
M i l l
hu m p53 CCCATCTCTCCCTCCCCTGCCATTTTGGGTTTTGGGTCTTTGAACCCTTGCTTGCAATAG
1 4 9 0
1 6 0 1 7 0
1 5 0 0 1 5 1 0
1 8 0 1 9 0 200
1 5 2 0 1 5 3 0 1 5 4 0
210
H2 6 9 4  GTGTGGGTCAGAAGCACCCAGGACTNCCATGANTGAGTGAATCGATAAAATAAAAGATTT
M i l l  I M I M M M M M I M M M M I
hum p5 3  GTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGGGCTCCACTGAACAAG
1 5 5 0
E
595208
Appendix: Sequence Alignment ofp53-Derived Cisplatin GSE's
b) 100.0% identity in 9 bp overlap
8 9  7 9  6 9  5 9  4 9  3 9  3 0
H2 6 94  GACTGTCAGTGGGGAACAAGAAGCATCTATCCATGAGCGTGGGACCACGGAGGCTGAATC
M I N I M I
hum p5 3 CATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTCT 
7 2 0  7 3 0  7 4 0  7 5 0  7 6 0  7 7 0
2 9  19  9
H 26 94  GAAANCGGTCGGGGGCCCTTAAGNCNNTT
hum p5 3 GGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGA 
7 8 0  7 9 0  8 0 0  8 1 0  8 2 0  8 3 0
Sequence Alignment of Forward (primer h2693) and Reverse 
(primer H2694) Primed Strands of mp53 PA3 B1
a) 69.5% identity in 141 bp overlap
1 9 9  1 8 9  1 7 9  1 6 9  1 5 9  1 4 9  1 4 0
H2 6 9 3 CACCAACAACCCTGTTTTGACCTCCATAAAACACCGGGGCCGATCCAACCTCCTCGCCTCmi : :  iiim mu | |
H2 6 94  GAAAGANCTTCATTGCGNCCACAACANTNTTGATCCAGTCTCCTTGGTCC
1 0  2 0  3 0  4 0  5 0
1 3 9  1 2 9  1 1 9 1 0 9  9 9  8 9  8 0
H2 6 93  CAAGCTTATGGATGGATGCATTCAGCTCCGGTTCCCACCGATCAAGGCGAGTTACATGAT
II II II I I I I I I I I I I : I I I I I I I I I I I I I M i l l  I I I  II  II II II I I I I  I I I M
H2 6 94  CACGCTTATGGATGGATNCATTCAGCTCCGGCNCCCAACGATCAAGGGGAGTTACATNAG 
6 0  7 0  8 0  9 0  1 0 0  1 1 0
7 9  6 9  5 9  4 9  3 9  2 9  2 0
H 26 9 3  TGATTGATTCGATCAGGGTCCAGGACCCTAATTATTCTCCAANNTTAAGGGNNCGGGNNC
I I I  I I I  I I I  I I I M II I I II M I N I  : :  I MM
H2 6 94  TGAGTGAATCGCT-AACATANAAGATTCGATCTAGTCTCCAGAAAAAGGGGGGAATGAAA 
1 2 0  1 3 0  1 4 0  1 5 0  1 6 0
75.0% identity in 16 bp overlap
9 0  1 0 0  1 1 0  1 2 0  1 3 0  1 4 0
H 26 93  TAACTCGCCTTGATCGGTGGGAACCGGAGCTGAATGCATCCATCCATAAGCTTGGAGGCG
II I I I  I I : I I I II
H2 6 9 4  NTTGATCCAGTCTCCTTGGTCCCACGCTTATGGATGGATNCATTCAGCTCCGGCNCCCAA 
3 0  4 0  5 0  6 0  7 0  8 0
F
Appendix: Sequence Alignment of p53-Derived Cisplatin GSE's
Sequence Alignment of mp53 PA3 B1 (H2693) With Human p53t, 
Accession no. K03199
a) 59.4% identity in 32 bp overlap
2 8 0  2 9 0  3 0 0  3 1 0  3 2 0  3 3 0
H 26 9 3  CNTCGTTNTTNCTGNAAACAAAATNAGNTCCTGCATNCNANCNNCA-CNCCCCCACCCCC
I II I : I : I : I : : I I h i  I I I  I I I I
hu m p53 TGACATTCTCCACTTCTTGTTCCCCACTGACAGCCTCCCACCCCCATCTCTCCCTCCCCT 
1 4 0 0  1 4 1 0  1 4 2 0  1 4 3 0  1 4 4 0  1 4 5 0
3 4 0
H 2 6 9 3  NCAGCTCTCG
: I
hu m p53 GCCATTTTGGGTTTTGGGTCTTTGAACCCTTGCTTGCAATAGGTGTGCGTCAGAAGCACC 
1 4 6 0  1 4 7 0  1 4 8 0  1 4 9 0  1 5 0 0  1 5 1 0
b) 100.0% identity in 9 bp overlap
3 4 9  3 3 9  3 2 9  3 2 0
H2 6 9 3 CGAGAGCTGNGGGGGTGGGGGNGTGNNGNT
I I I I I I I I I :
h u m p53 ATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAG 
1 2 1 0  1 2 2 0  1 2 3 0  1 2 4 0  1 2 5 0  1 2 6 0
Sequence Alignment of mp53 PA3 B1 (H2694) With Human p53t, 
Accession no. K03199
a) 70.8% identity in 24 bp overlap
1 0 9  9 9  8 9  7 9  6 9  5 9
H2 6 9 4  CTCACTNATGTAACTCCCCTTGATCGTTGGGNGCCG-GAGCTGAATGNATCCATCCATAA
h  I I I  1111111111: II I
hu m p53 TCAGATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACT 
1 2 1 0  1 2 2 0  1 2 3 0  1 2 4 0  1 2 5 0  1 2 6 0
b) 76.9% identity in 13 bp overlap
5 0  6 0  7 0  8 0  9 0  1 0 0
H 26 9 4  CTTGGTCCCACGCTTATGGATGGATNCATTCAGCTCCGGCNCCCAACGATCAAGGGGAGT
l l l l l l l  h i  I
h u m p53  AGGCTGCTCCCCCCGTGGCCCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAG 
4 2 0  4 3 0  4 4 0  4 5 0  4 6 0  4 7 0
G
Appendix: Sequence Alignment of p53-Derived Cisplatin GSE's
Sequence Alignment of Forward (primer h2693) and Reverse 
(primer H2694) Primed Strands of mp53 PA2 B1
a) 65.7% identity in 201 bp overlap
2 2 9  2 1 9  2 0 9  1 9 9  1 8 9
H 2 6 93  CCNTGGAGACGCCATCCACACTAATTTGACCTCCATAGNAGACGC CGGGTCCGATCC
I h l l l  | : | | l  I I I  M I N I
H 26 9 4  TCNGTGNNNANACACTNCATTGTTG2CACAANAGGTTTCGATCC
1 0  2 0  3 0  4 0
1 7 9  1 6 9  1 5 9  1 4 9  139 1 2 9
H 26 9 3 a g c c t c c g c g c c c c c a a g c t t a t g g a t g g a t g c g g g a t a c \ a A t t t c c t t c c c a g c c g g a
II  M i l l  I M h  I I I I I I I I I I I I  I I I  I I I  111IIII I1111111 I I I  M i l l
H 2 6 9 4  AGTCTCCGTGGTNCCNCGCTTATGGATGGATGCGGTATAC\a ATTTCCTT-CCACCCGGA 
5 0  6 0  7 0  8 0  9 0  1 0 0
1 1 9  1 0 9  9 9  8 9  79 6 9
H2 6 9 3 TAAGATTCCTGGGGAGGAGCCCAGTCCCATGAGTTGATTGVT'ffCCGATGCGGGGCCCCAG
l l l l l l  I 11111111111 I II M i l l  I I I  III II I I I I  I
H 2 6 9 4  TAAGATGCTGGGGGAGGAGCCAGG— CCATGAG-TGAGTG^lF-CGAT— AAAATAAAGG 
1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
5 9  4 9  3 9  2 9  9 9
H 26 9 3  a t t t t a t t t a t t c t a a a n a a t t t t t g g g n c n g g n a g a a a t s c n t n c t a n n n g a n n n a n n n t
I I I I I I I I I I I I I  h l l  l l h  : I M I h ::  I I : : : I
H 2 6 9 4  ATTTTATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCCA^CCTGTAGGTTTGGGAAG 
1 6 0  1 7 0  1 8 0  1 9 0  I00) 2 1 0
b) 73.3% identity in 15 bp ove’lajp
1 9 0  2 0 0  2 1 0  2 2 0  2 3 (  2 4 0
H 26 9 3 CCGGCGTCTNCTATGGAGGTCAAATTAGTGTGGATGGCGTCTCJCANGGACA
l l l l l l  II I l h
H2 6 9 4 ATCCAGTCTCCGTGGTNCCNCGCTTATGGATGGATGCGGTiTAiCAAATTTCCTTCCACCC 
5 0  6 0  7 0  8 0  9 0  1 0 0
Sequence Alignment of mp53 PA2 B1 (H26S3)) With Human p53t, 
Accession no. K03199
a) 81.2% identity in 48 bp oveiapp
7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
H2 6 9 3 GGGCCCCGCATCGGAATCAATCAACTCATGGGACTGGGCTCTCCCCCAGGAATCTTATCC
II II I I I  l l l l l l  II I I I I I I I I I I
hu m p53 CCCCACCATGAGCGCTGCTCAGATAGCGATGGTCT-GGCCCTCCCTCA-GCATCTTATCC 
7 5 0  7 6 0  7 7 0  7 8 0  7 9 0  8 0 0
1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0
H2 6 9 3 GGCTGGGAAGGAAATTTGTATCCCGCATCCATCCATAASCOTGCfGGGGCGCGGAGGCTGGA
I I I I I I I I I I I I I I I
hu m p53 GAGT-GGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGlAAACACTTTTCGACATAGT 
8 1 0  8 2 0  8 3 0  840 8 5 0
H
Appendix: Sequence Alignment ofp53-Derived Cisplatin GSE's
b) 63.3% identity in 49 bp overlap
8 9  7 9  6 9  5 9  4 9  3 9
H2 6 9 3 ATGAGTTGATTGATTCCGATGCGGGGCCCCAGATTTTA--------- TTTATTCTAAANAATTT
I I II I I II I I I I  I I I : II I
hum p5 3  AGGAGGATGGGGAGTAGGACATACCAGCTTAGATTTTAAGGTTTTTACTGTGAGGGATGT 
1 5 9 0  1 6 0 0  1 6 1 0  1 6 2 0  1 6 3 0  1 6 4 0
2 9  1 9  9
H 26 9 3 TTGGG-NCNGGNAGAAATGCNNCTANNNGANNNANNNT
M i l l  : : I M I N I M
hum p5 3  TTGGGAGATGTAAGAAATGTTCTTGCAGTTAAGGGTTAGTTTACAATCAGCCACATTCTA 
1 6 5 0  1 6 6 0  1 6 7 0  1 6 8 0  1 6 9 0  1 7 0 0
Sequence Alignment of mp53 PA2 B1 (H2694) With Human p53t, 
Accession no. K03199
a) 89.6% identity in 48 bp overlap
1 5 9  1 4 9  1 3 9  1 2 9  1 1 9  1 0 9
H 2 6 9 4  AAATCCTTTATTTTATCGATTCACTCACTCATGGCCTGGCTCCTCCCCCAGCATCTTATC
I I I I  M i l l  I I I  II I I I I11111111
hu m p53  GCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTCTGGCCCCT-CCTCAGCATCTTATC 
7 5 0  7 6 0  7 7 0  7 8 0  7 9 0
9 9  8 9  7 9  6 9  5 9  4 9
H 26 9 4  CGGGTGGAAGGAAATTTGTATACCGCATCCATCCATAAGCGNGGNACCACGGAGACTGGA
II I II  I II  I I I I I I I I I
hu m p53  CGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACATAGT 
8 0 0  8 1 0  8 2 0  8 3 0  8 4 0  8 5 0
b) 59.1% identity in 66 bp overlap
7 0  8 0  9 0  1 0 0  1 1 0  1 2 0
H 26 9 4  CGCTTATGGATGGATGCGGTATACAAATTTCCTTCCACCCGGATAAGATGCTGGGGGAGG
I I I I I I II  I M i l l  II I
hum p5 3 ------------------------------------------------------GTCGACCCTTTCCACCCCTGGAAGAT-------- GGAAATA
1 0  2 0  3 0
1 3 0  1 4 0  1 5 0  1 6 0  1 7 0  1 7 9
H2 6 9 4 AGCCAGGCCATGAGT- GAGTGAATCGATAAAATAAAGGATTTTATTTAGTCTCCAGAAAA
I II  I II II M i l l  II  I I I I  I I I
hu m p 5 3 AACCTGCGTGTGGGTGGAGTGTTAGGACAAAAAAAAAAAAAAAAAAGTCTAGAGCCACCG 
4 0  5 0  6 0  7 0  8 0  9 0
GLASGOW 1 
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